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Summary 
In this introductory chapter cyclosporin A is presented with its historical background, its 
properties and applications. After its discovery in 1973 it was found to have immunosup-
pressive qualities, different from the compounds so far in use. It proved to be an (almost) 
perfect medicament to prevent organ graft rejection. Soon much research provided us 
with a boom of information on the drug and its immunopharmacological properties. 
During a study on its effectiveness in arthritis, it was noted to have an antipsoriatic effect 
in a case with psoriatic athropathy. After that experience many immune diseases were 
treated, also in the field of dermatology. An impressive list of some 30 diseases is shown, 
however, among these psoriasis seems to react the most convincingly. 
Introduction 
Since its introduction in the 1970's cyclosporin A (CyA) has become the drug of first 
choice for use in transplantation centers to prevent organ-graft rejection. The therapeutic 
potential of CyA was accidently discovered as a side-effect when patients with arthritis 
psoriatica were treated. The idea of its use as a trial drug to treat psoriasis lasted about 
another ten years. On the basis of theories of its mechanism of action, the in vitro studies 
and the numerous clinical trials (and errors) in organ transplantation which are briefly 
summerized in this chapter, a firm step could be made into the realm of dermatology to 
determine the clinical efficacy of this drug, especially in psoriasis, a disease with an 
acknowledged immunological background. 
History 
During a search for new antifungal agents, soil samples were obtained from the Hardan-
ger Vidda, a large treeless highland plateau in the southern part of Norway in the early 
seventies. The fungus Tolypocladium Gams was isolated from these samples. In 1973, its 
most important metabolite cyclosporin A was purified, but was observed to have only 
mild antifungal activity [1-3]. In an additional screening program, however, Borel showed 
that cyclosporin A has substantial immunosuppressive properties in the absence of major 
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mitogenic or myelotoxic effects at pharmacological doses [4]. 
CyA belongs to the cyclic peptides, a group of structurally related compounds. The novel 
amino acid at position one and its three dimensional structure seem to be relevant for its 
activity [5]. 
Pharmacology and pharmacokinetics 
The molecular formula of CyA is C62 H111 Nll 012 and its molecular weight is 1202 
Dalton [4]. Cyclosporin A is a white crystalline powder. It is a fermentation product of 
the mycelia of two strains of fungi imperfecti of the species To1ypoc1adium inflatum 
Gams and Cylindrocarpum lucidum Booth. Cyclosporin A is hydrophobic and is insoluble 
in aqueous solutions. It must, therefore, be dissolved in lipids before administration. The 
oral route is most commonly used, but it can also be administered intravenously or via 
intramuscular and intracutaneous administration though these routes are painful. 
An effective formulation for the topical application of CyA is not yet available (see 
Chapter 6). In all known metabolites, the structure of CyA is preserved (Fig. 1) [6]. 
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Fig. 1. Chemical structure of cyc\osporin A. 
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Absorption 
After oral ingestion, CyA is absorbed in the small intestine [7]. The amount absorbed 
depends on the gastrointestinal function, the transit time and the quantity of bile [8,9]. 
This explains the (inter)individual and daily fluctuations in CyA levels. About 98% of the 
drug appears in the portal circulation. The rest (2%) may then exert its first immunosup-
pressive effect on circulating lymphocytes via the thoracic duct [10]. On average 28% of 
the administered oral dose is recovered in the systemic circulation. The presence of 
normal serum low-density lipoprotein levels, the intake of CyA with food and prolonged 
therapy promote the absorption of the drug [11]. The course of the blood concentration-
time curve shows a sharp peak at 1.5 to 6 hours [12]. Following intramuscular adminis-
tration, the absorbtion is less and the variability is greater than after oral administration. 
Recently, topical application of CyA was observed to result in a transcutaneous passage of 
CyA to an amount that produced noticable therapeutic effect in some T cell-mediated skin 
disorders without general side-effects (this subject is discussed in Chapter 6). 
Distribution in blood 
The distribution in the central compartment depends on several factors such as absolute 
Cy A concentration, time, temperature and hematocrit. Erythrocytes demonstrate a tenfold 
greater CyA binding affinity than lymphocytes [13-15]. In vitro studies showed that CyA 
rapidly accumulated in the cytoplasm and nucleus of mononuclear cells and granulocytes 
[16] and is partly bound to intracellular/cytosolic macromolecules such as cyclophilin, 
calmodulin and related Ca2+ dependent proteins [17-24]. Another factor that dictates the 
distribution in blood is the level of (high and low density) lipoproteins since CyA binds to 
these plasma constituents [25-26]. The binding affinity is low and CyA is readily available 
for distribution into the peripheral compartment. 
Distribution in peripheral tissue compartments 
From the plasma, free CyA passes into the interstitial fluid where it binds to lipoproteins 
once again. Investigations using suction blister fluid showed that whole blood and blister 
fluid (the analogue of interstitial fluid) concentration-time curves were paralleL This is 
also true for levels measured in synovial fluid from patients with rheumatoid arthritis who 
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were treated with CyA [27]. The concentration of CyA in blister fluid, however, is only 
1/10th of that in whole blood [28-32]. 
The end concentration of CyA in the skin probably determines the effects in skin 
disorders. A recent study may illustrate this. Skin plaques of patients with psoriasis after 
7 days of systemic treatment (14 mg/k!g) contain comparable concentration of CyA as the 
buccal mucosa in oral lichen planus patients treated with 500 mg 3 times daily using the 
rinse method (2.3 ± 0.3 versus 2.1 ± 0.3 ng CyA/mg tissue) [33]. 
After prolonged administration, other tissues usually contain high concentrations of CyA, 
e.g. body fat, liver, spleen, pancreas, kidney and lymph nodes [34]. Although these 
organs store the parent compound, the slow release of CyA does not seem to guarantee 
effective drug levels after cessation of treatment [35]. Saturation of the peripheral 
compartment, however, may result in decreased amounts of CyA being required for long-
term treatment. 
Metabolism and excretion 
CyA is metabolized in the liver by the cytochrome-P450 system [12]. The resulting 
metabolites are excreted via the bile into the faeces. Enterohepatic recirculation has been 
reported [11]. Only 10% of biodegraded CyA is excreted into the urine [13], and because 
of this low level of urinary excretion, renal failure hardly alters CyA elimination [36]. A 
mere 1% of the unchanged drug could be detected in the faeces. These amounts may be 
altered by diseases or drugs which affect liver functions (see drug interactions and Table 
3). 
Drug clearance rates are low in elderly patients and in patients with decreased levels of 
serum low-density lipoprotein triglyceride and cholesterol and in patients with hepatic 
impairment [37]. 
Concentration measurements 
As a consequence of the inter-individual differences in gastrointestinal absorption, hepatic 
biotransformation, excretion and tissue response, the measurement of CyA levels is 
regarded to be important for monitoring treatment and toxicity [38-45]. Currently three 
analytical techniques are in use. These are radioimmunoassay (RIA) [46,47], fluo-
rescence-polarization-immunoassay (FPIA) [48] and high performance liquid chromato-
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graphy (HPLC) [49]. Whole blood levels are about three to five times higher than plasma 
levels because CyA is adsorbed onto erythrocytes (vide supra) [36] which makes 
procedures for analyzing whole blood the most preferable. Parent drug only is measured 
using HPLC whereas, the polyclonal antiserum used in FPIA and RIA detects both CyA 
and its metabolites. As a result the trough levels are two to four times higher. The 
polyclonal antiserum to CyA for use in RIA and FPIA was recently substituted by a 
monoclonal antibody [50]. In clinical practice serial determinations of trough levels and 
doses between estimated adequate trough level-values appear an appropriate guideline 
[51]. 
Action spectrum 
In vitro and animal studies 
Borel and co-workers showed in their studies that CyA had a strong inhibitory effect on 
the proliferative response of T-cells stimulated by (allo)antigens and various mitogens. 
The effect on antibody synthesis, a B-lymphocyte response was minimal or absent. They 
concluded that T-lymphocytes were the target cells of CyA [4,52,53]. A T-cell response 
is triggered when antigens are expressed and recognized. This occurs when antigen 
presenting cells (APCs) such as macrophages, dendritic cells and Langerhans cells with 
class II major histocompatibility molecules on their surface present the antigen to T-
helper/inducer cells. These are subsequently activated and release mediator proteins called 
lymphokines, which belong to the larger group of mediator proteins called cytokines. 
Interleukin-2 (IL-2), one of the lymphokines is a growth factor for T-cells and is 
responsible for clonal expansion. It is thus an autocrine growth factor for activated T-
helper/inducer cells and a paracrine growth factor for cytotoxic T-cells [54]. 
Sensitive assays were used to study these phenomena in vitro and in vivo [reviewed in 
reference 55]. The production of ll-2 appears to be inhibited by CyA and consequently 
the proliferation of most T -cells is blocked. T -suppressor cells which generally have a 
low proliferative activity are not so much influenced by CyA and do not show a substanti-
al reduction in number following CyA treatment (56-58]. CyA has no effect on T-cells 
that are already stimulated by IL-2. The effect on the expression of the IL-2 receptor is 
unknown. 
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Apart from the action on T-cells, CyA also affects APCs [59-61]. Macrophages are even 
more sensitive to CyA than T-cells regarding the inhibition of IL-2 production [62]. 
Similarly the drug inhibits the synthesis of gamma-interferon, the lymphokine that 
provides an amplification signal activating macrophages and monocytes [63]. 
In several disease states CyA may exert additional effects on activated cells of the 
involved organs. With regard to skin diseases, investigations are now also focused on 
keratinocytes, endothelial cells, granulocytes and fibroblasts [64-68]. 
The exact mechanism of immunosuppression of Cy A has not yet been elucidated (Table 
1). The existence of a specific CyA-receptor cyclophilin (or peptidyl-prolyl cis-trans 
isomerase) suggests inhibition of an early intracellular event in T-cell activation by CyA 
[69]. An influence on the transcription of mRNA coding for molecules like IL-2 has also 
been proposed [70,71] but a pretranslational interference has not been ruled out [72]. 
Table 1 
Aspects of the action spectrum of Cy A 
CyA does not inhibit the recognition of an antigen by the T-cell receptor 
CyA does not interfere with transmembrane signalling 
CyA diffuses passively through the cell membrane 
CyA is intracellularly bound to a specific receptor (cyclophilin) 
CyA inhibits transcription of mRNA for many lymphokines, e.g. IL-2 
CyA reduces synthesis of other activation antigens and expression of Major Histocompati-
bility Complex gene products 
Clinical efficacy in organ transplantation and auto-immune diseases 
In 1978 Calne et al demonstrated that CyA was extremely effective in preventing rejection 
of renal allografts [73]. After this success other organ transplants could be realized (heart, 
heart-lung, pancreas, bone-marrow, liver) [74]. Apart from the difficulties encountered in 
each case the adverse effects of CyA at relatively high doses (up to 25mg/k/d) also 
became apparent. The immunomodulating effect of CyA was also evaluated in a range of 
auto-immune diseases, some of which have dermatological aspects [75]. In a pilot study 
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to determine the efficacy of CyA in arthritides, it appeared that the skin lesions of a 
patient with psoriatic arthritis resolved [76]. 
Use in dermatological disorders 
Besides the above mentioned diseases with an acknowledged immunological background 
several other diseases with a known or suspected T-lymphocyte mediated pathology were 
included to investigate the effects of CyA (Table 2). In this table even some conditions 
with questionable immunological background are listed. The exact mode of action of CyA 
in these conditions is not clear at present. 
After the experiences of Mueller and Hermann [77], a few incidental cases reporting the 
clearance of psoriatic lesions during CyA treatment in transplant recipients were published 
[78,79]. 
These reports raised the question whether Cy A could be of therapeutic value in treating 
dermatological diseases in general and psoriasis in particular. 
Table 2 
CyA studies in diseases with dermatological aspects other than psoriasis 
Disease References 
l. Actinic reticuloid [80] 
2. Alopecia areata [81,82] * 
3. Alopecia, male pattern [83] * 
4. Atopic dermatitis [84-90] * 
5. M. Behcet [91-94] 
6. Contact dermatitis [95-96] * 
7. M. Crohn [97-100] 
8. Dermatomyositis [101-108] 
9. Eosinophilic fasciitis [109] 
10. Epidermolysis bullosa acquisita [110-112] 
11. Erythema multiforme [113] 
12. Erythema nodosum leprosum [114] 
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Table 2 (continued) 
Cy A studies in diseases with dermatological aspects other than psoriasis 
Disease 
13. Graft versus host disease (GVHD), cutaneous 
14. Ichthyosis 
15. Lichen planus/ -oris 
16. Lupus erythematosus variants 
17. Mycosis fungoides (cutaneous T-celllymphoma) 
18. Pemphigoid, bullous 
19. Pemphigus variants 
20. Persistant light reaction 
21. Pityriasis rubra pilaris 
22. Pyoderma gangraenosum 
23. Scleroderma 
24. M. Sezary 
25. M. Sjogren 
26. Toxic epidermal necrolysis (TEN) 
27. Ulcerative colitis 
* CyA was applied topically (see references of Chapter 6). 
Known side-effects and drug interactions 
Known side-effects 
References 
[115-117] 
[118,119] 
[120] * 
[121-127] 
[128-132] 
[133-135] 
[136-140] 
[141] 
[142] 
[143-147] 
[148-150] 
[151-154] 
[155] 
[156] 
[157] 
Clinical trials in humans with high doses CyA have rendered much information on drug 
induced complications. Lower doses (about 5 mg/kg/d) tended to cause less side-effects 
but long-term regimens may evoke new problems [158]. 
Nephrotoxicity and hypertension [159,160], both in part related to vasoconstriction are the 
most frequent adverse effects. Dose reductions seemed to prevent further deterioration 
[161, 162]. Apart from acute toxicity and loss of (transplanted) kidneys [163], the early 
sign of an impact on kidney tissue is of functional nature with minimal structural changes. 
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After prolonged administration, however, structural changes were visible in the renal 
biopsies [164]. Mihatsch et al distinguished tubular toxicity (atrophy, oedema and 
collagen ingrowth or the appearance of giant mitochondria and microcalcification) and a 
chronic vasculointerstitial syndrome involving the vessels. These anatomical changes were 
partly irreversible [165]. The same observations were made in cases other than transplant 
recipients [166,167]. Explanations for these observations are only hypothetical [57,168-
171]. 
Administration of nephrotoxic drugs before or during CyA treatment like the use of non 
steroid anti inflammatory drugs (NSAIDs) in rheumatoid arthritis may accelerate the 
effect of CyA on the kidneys [172,173,27] (see Table 3). 
Hypertension is a time and dose related effect in over 20% of the patients [158]. Apart 
from dose reductions, antihypertensive drugs may help to control this reaction. An 
increase in serum lipid values and a deterioration in carbohydrate metabolism has been 
reported [174-177]. The role of CyA per se in bacterial, fungal and viral infections could 
not be substantiated as these were frequent in transplant recipients [172, 176, 178]. 
Myelotoxicity seemed to be absent [4] but lymphoproliferative disorders may evolve. 
Epstein-Barr virus infections may account for increased proliferation of the B-lymphocyte 
pool and induce B-celllymphomas [179-183] but a reactive B-cell amplification may also 
follow T-cell suppression insidiously [184-185]. Cutaneous neoplasms can be a manifesta-
tion of decreased immunosurveillance and as such, be a part of the induced immunodefi-
ciency syndrome in an organ transplant patient [186-189]. 
Breast fibroadenomas in females as well as in males (gynecomastia) have been reported 
[163,190,191]. Hypertrichosis on the face, arms, eyebrows and back is a frequent side-
effect, but mainly bothersome in women. For these effects an endocrine influence is still 
debated [192]. 
Gingival hyperplasia is comparable with the phenytoin induced reaction [163,164,191,-
193]. Frequent neurological signs are tremors and burning paraesthesias including leg 
cramps [163,172,191]. Epileptic seizures and psychosis are seldom [191]. Depression has 
often been seen. Hepatotoxicity was reported with small evaluations in serum bilirubine 
and transaminase levels attributed to cholestasis [163,164,172,191]. Minor gastrointestinal 
symptoms (nausea, vomiting or diarrhoea) can occur in the first weeks of therapy and can 
interfere with intake and resorption of CyA [191]. These symptoms contrast with the 
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observations that the drug has no direct toxic effects on the structure or function of 
gastrointestinal mucosa. 
Many of the reported side-effects are dose related and reversible. 
Drug interactions 
A number of drugs have been reported to interact with CyA [194]. Substances that are 
known to induce or inhibit the cytochrome-P450 complex in the liver either decrease or 
increase CyA trough levels (Table 3). 
The hazardous relationship between nephrotoxic drugs and Cy A treatment, has been 
mentioned earlier (see also Table 3). 
Table 3 
A summary of drugs that influence the blood trough levels of cyclosporin and increase the 
risk of renal dysfunction [references 194-201]. 
Increase Cy A level 
aciclovir 
amphotericin B iv 
cimetidine 
prednisolone 
diltiazem 
doxycycline 
ketaconazole 
erythromycin 
nicardipine 
oral contraceptives 
Decrease Cy A level 
barbiturates 
carbamazepine 
phenytoin 
isoniazide 
rifampicin 
Increase nephrotoxicity 
amphotericine B iv 
aminoglycosides iv/im 
melphalan 
NSAIDs 
trimethoprim + 
sulphamethoxazo1 
furosemide 
cefuroxime 
Undoubtedly, the introduction of CyA is a welcome and unique addition to the range of 
dermatological treatment modalities. The advances in our understanding of immunological 
phenomena and the progress on the knowledge of the action mechanism(s) of CyA will 
enable us to use the drug even more effectively. In Chapters 3-8 the application of CyA 
in psoriasis is discussed in details. 
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Summary 
The spectrum of clinical manifestations of psoriasis are presented with a description of the 
histopathology of the different morphological variations. 
These data and currently known array of abnormalities that are observed in the spectrum 
of manifestations in psoriasis such as hyperproliferation, dyskeratinization, vascular alte-
rations, the role of immune cells [1,2] and other mediators of inflammation are surveyed 
to explain some of the aspects of the pathomechanisms in psoriasis. In order to obtain an 
overview of the present state of pharmacological manipulation of these phenomena the 
literature on currently used therapies, some experimental approaches and their suspected 
mode of action, clinical results and adverse effects is reviewed. 
Introduction 
Psoriasis is a commonly occurring skin disease with a prevalence of about 2% and an 
equal sex distribution in Western Europe: Although considerable effort has been directed 
into research on the pathogenesis of psoriasis, the exact causal factor of the disease 
remains elusive. 
Three suppositions for a mode of heridity are postulated. These are disease heterogeneity, 
polygenic determination and autosomal dominant inheritance with incomplete penetrance 
[3]. 
Apart from this genetic component, triggering factors can be recognized. After exogenous 
(mechanical) traumas like itching or endogenous luxating moments such as (focal) 
infections, endocrine inbalance, psychogenic stress or the use of particular drugs (lithium, 
fi blockers) the skin of susceptible individuals may show psoriasis or psoriasiform 
reactions (the isomorph Koebner phenomenon). Special attention has been drawn to the 
immunopathogenesis of psoriasis which offers an attractive model to explain many of the 
observed abnormalities such as epidermal hyperproliferation, dyskeratinization and 
inflammation. An inflammatory infiltrate together with a dysregulation in the production 
of cytokines [4-6] may also contribute towards the clinical presentation of the disease. 
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Clinical manifestations 
Clinically, patients with psoriasis present skin lesions accompanied by erythema and 
desquamation. Preferential locations of the disease are elbows, knees, sacral area and the 
scalp but the palms and soles and the flexures or nails may also be involved, be it with a 
modified presentation. The initial diagnosis is supported by routine procedures such as a 
gentle "grattage" which produces a characteristic silver-white lining (candle-wax appea-
rance) and the removal of adherent scales easily results in pinpoint bleedings (Auspitz' 
sign) [7,8]. 
The considerable variation in the clinical presentation of the disease results in a wide 
range of psoriasiform patterns [7, 8]. 
In guttate psoriasis, small erythemato-squamous lesions (diameter up to 1.5 em) are 
typically located on the trunk and proximal part of the extremities. In children, it has a 
benign course but in adults it usually shows a more stubborn character. 
In annular psoriasis, ring-formed lesions with an inactive central region are observed. 
However, patients with psoriasis usually present sharply demarcated lesions varying from 
a few centimeters (nummular type) to large areas (plaque type) with a variable degree 
of infiltration. In these most common variants which usually follow a chronic course 
preferential sites are generally affected. 
In erythrodermic psoriasis, the individual lesions have fused to form a generalized 
pattern of redness and scaling. This form of psoriasis is rather uncommon. 
Pustular psoriasis is characterized by ·sterile pustules occurring locally or generally. 
Psoriasis of the palms and soles (Andrews-Barber disease) and acrodermatitis continua of 
Hallopeau on fingers or toes are very resistant to treatment. 
An acute reaction predominantly consisting of small pustules scattered over the entire 
erythematous skin has been described by Von Zumbusch [8]. 
Seronegative arthritis (psoriasis arthropathica) is an extracutaneous manifestation of 
psoriasis [7, 8]. 
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Histopathology 
The variations of the histological changes in psoriasis highly depend on the clinical type 
and on the stage of the disease [9,10]. 
In the macroscopically unaffected skin, modest epidermal hyperplasia and hypergranula-
rity together with a condensed horny layer can prelude (as potential pre-psoriasis) the 
development of clinical psoriasis. 
In the newly developing pinhead lesion, moderate epidermal hyperplasia and acanthosis 
of a few rete ridges and focal dilatation of the epidermal intercellular spaces are obser-
ved. Some macrophages and lymphocytes invade the epidermal malpighian layer in this 
early phase. 
Polymorphonuclear leucocytes (PMNLs) invading the epidermis are observed after a few 
days [11]. In the dermis a perivascular infiltrate consists of lymphocytes and macrophages 
with a few PMNLs, while there is papillary edema and dilatation of the capillaries. 
In guttate psoriasis, a focal epidermal hyperplasia, spongiosis and parakeratosis are 
observed. The granular layer over these foci disappears and the invading PMNLs 
accumulate in a network of degenerated stratum spinosum cells [12]. In the dermis the 
capillaries spiral high into the tops of the edematous papillae (squirting papillae) [10]. 
Lymphocytes and PMNLs aggregate in the parakeratotic mounds and form a perivascular 
infiltrate. 
The margin of a psoriatic plaque shows the most prominent and typical characteristics 
such as a regular elongation of the rete ridges with thickening in their lower portions, 
thinning of the suprapapillary area and absence of a granular layer. Above the basal layer 
two cell rows with many mitoses are observed [10]. In the upper stratum Malpighii there 
is edema and spongiform pustule formation. Parakeratosis and Munro microabcesses are 
present in the corneal layer. The dermal papillae are long and club-shaped and the dilated 
capillaries are turtuous. The infiltrate in the epidermis consists of PMNLs [11] and in the 
dermis a mild infiltrate consisting of mononuclear cells is visible [colour plates 7 and 8]. 
The histology of psoriatic erythroderma also shows acanthosis, parakeratosis and 
changes in and above the tops of the dermal papillae but here exudation and dilated 
capillaries are more prominent. 
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In typical pustular psoriasis, spongiform pustules of Kogoj are located in the stratum 
Malpighii as a result of increased exocytosis of PMNLs. When the pustules move 
upwards the PMNLs become pycnotic and form large intracorneal microabcesses. This 
process may develop so rapidly that there is only a slight epidermal hyperplasia. In 
pustular psoriasis also dilated vessels in the edematous dermal papillae are surrounded by 
an infiltrate with lymphocytes and some PMNLs [10]. 
Microcirculation 
An integral component of the psoriatic lesions are the microcirculatory vessels of the 
horizontal plexus in the dermis and the capillary loops [13,14]. The capillaries become 
dilated and tortuous in early lesions. Light microscopy examination shows that the 
capillary loops in psoriasis display the characteristics of venous capillaries with single or 
multilayered basal membrane material in the wall and the presence of bridged fenestrati-
ons in the endothelial layer. Endothelial cell gaps are present particularly in the postca-
pillary venules. These gaps may be responsible for the loss of plasma proteins and 
exocytosis of lymphocytes [15]. 
Electron microscopy 
Detailed information on the ultrastructural pathology of psoriasis is now available 
[7,12,16]. The surface of a skin lesion shows a discontinous arrangement of scales and 
wide intercellular gaps. Filiform protrusions are observed around keratinocytes at all 
levels, which may be a sign of immaturity due to the higher metabolic activity in psoriatic 
skin and due to accelerated upward transit of the cells. The higher metabolic activity may 
be concluded from the increased number of cell organelles like mitochondriae, ribosomes, 
Golgi apparatus and a prominent endoplasmic reticulum. The increased volume of the 
psoriatic lesion is caused by hyperplasia (increase in cell number) and hypertrophy 
(increase in cell size by edema). Parakeratosis (the persistence of nuclear residues), 
delayed flattening of the cells and irregular thickness of the cell membrane are also signs 
of immaturation. In psoriasis, the cytoskeleton, which is the structural keratin framework 
important for cell shape and intracellular compartmentalization is abnormal. The number 
of tonofilaments is reduced, the depolimerization of microfilaments in the corneal layer is 
absent and the anchoring of tonofilaments in the microtubules is chaotic. The number of 
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desmosomes is reduced, whereas the gap junctions have increased in the upper layers. 
The relevance of virus-like particles observed in psoriasis has not yet been clarified [17]. 
Pathomechanisms 
Two main approaches on the pathomechanisms in psoriasis have been proposed. These 
are a primary metabolic abnormality and a primary immunologic dysregulation [6]. 
Metabolic aspects 
In psoriatic lesions, keratinocytes show a range of biochemical abnormalities. Although 
an abnormal proliferation may be genetically controlled, gene-mapping studies have not 
yet provided more information on a distinct modification at this level [3]. In the cytosol, 
several compartments are involved in an aberrant metabolism. In the Golgi apparatus 
increased glycosylation occurs, e.g. the fucose incorporation into glycoprotein is 3 times 
higher. The lysosomes produce 20-30 times more 13-glucosidase and arylsulphatase A and 
B. Mitochondrial enzyme activity is increased. The lipid content of the plasma membrane 
is increased [8]. Transmembranous signal transducing systems are altered [5]. Adenylate 
cyclase-cAMP, guanylate cyclase-cGMP, phospholipase C-diacylglycerol/inositol 1,4,5 
triphosphate and epidermal growth factor-tyrosine kinase are all altered. As a result 
intracellular protein phosphorylation is increased and this is associated with enzyme 
activation (orthine decarboxylase and phospholipase A;). The keratins of the cytoskeleton 
and cornified cell-envelope are grossly altered. The suprabasal 65-67 kD keratins are 
reduced or absent, whereas the amount of 50 and 58 kD keratins is decreased in the basal 
layer but increased weakly in the supralayers [8]. For high enzyme activity more calcium 
(free or protein bound) is needed. The Ca2+ binding protein, Calmodulin, is increased in 
psoriatic skin [19]. External stimuli such as growth factors and hormones induce 
biochemical changes which in tum function as a messenger system to various tissues or 
cell compartments. 
Cell functions and cell-cell interactions 
The main focus of investigation has been epidermopoiesis for considerable time [6]. 
Histologically besides keratinocytes other cell types are also relevant in psoriasis. In 
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psoriasis the germinative pool of actively cycling keratinocytes consists of 2-3 cell layers 
instead of one and the production rate is calculated to be 20 times higher than that in 
normal skin. The cell cycle is apparently normal in psoriasis but the migration from the 
basal layer until desquamation is approximately 10 times faster [8]. 
An increase of metabolic products (hydroxyproline, uronic acid, glycosaminoglycans) and 
the occurrence of less cross-linked collagen indicate that fibroblasts also play a role. In 
vitro, fibroblasts can induce hyperproliferation of epidermal cells [19]. The action of 
interferon (IFN) -gamma and interleukins (ILs) on the endothelial cells results in a 
derangement of the vascular pattern. 
In the formation of micro-abcesses and overt pustulosis, accumulation of PMNLs occurs 
[11,20,21]. The number of dendritic cells and lymphocytes in the epidermis in psoriatic 
skin suggests an ongoing immunological process (cell-mediated immune response) 
[5,6,22]. 
As a putative immunologic stimulus in psoriasis many candidates have been suggested. 
These include auto-immunogens like a stratum corneum derived fraction and allo-immun-
ogens such as retrovirus protein P27 [23]. Cells with dendritic morphology, Langerhans 
cells are supposed to be accumulated in the skin for antigen presentation [24]. The 
lymphocytes infiltrating into the (sub)epidermis are activated T-cells. The T-cell hel-
per/suppressor ratio depends on the clinical state but the T-cell helper/inducer subset 
forms the majority [5]. Activated T-cells secrete cytokines like IL-2, that maintain and 
control the immune response but are also thought to stimulate epidermal growth [25]. 
Keratinocyte-lymphocyte interactions are considered to play a major role in psoriasis. One 
of the intergrins namely lymphocyte function associated antigen-! (LFA-1) reacts with 
intercellular adhesion molecule-! (ICAM-1) of activated keratinocytes mainly in those 
parts of the epidermis that overlay the top of the dermal papillae, thereby recruiting 
lymphocytes from the circulation [26]. Immunomodulating drugs like CyA which interfere 
with IL-2 dependent T-cell proliferation are thought to slow down keratinocyte prolife-
ration in psoriasis. 
For intercellular communication many mammalian cells secrete substances into the 
extracellular matrix. These mediators can also be involved in adhesion, growth regulation, 
cell migration and vasodilatation in the skin [27,28]. In psoriasis many molecules are 
suspected to play a role in the induction of abnormal proliferation and inflammation [5]. 
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The family of eicosanoids, which have inflammatory mitogenic properties also play a 
role. Some of the metabolites are elevated in psoriasis. Leukotrienes, especially LTB4 , are 
chemoattractants for PMNLs [11]. Prostaglandines like PG~ and PGF2• cause vasodilata-
tion and probably epidermal proliferation [5,6]. 
Platelet activating factor (P AF) activates cell functions in combination with phospholipase 
C and Epidermal Growth Factor (EGF). Mononuclear cell derived lymphokines effect 
mitotic activity and parakeratosis. Interleukins from Langerhans cells, granulocytes and 
keratinocytes cause inflammation (granulocyte immigration, erythema and edema) and are 
able to activate keratinocytes, lymphocytes as well as fibroblasts and endothelial cells [5]. 
Complement factors deposited in psoriatic epidermis may be activated by anti-stratum 
corneum antibody-stratum corneum antigen complex formation. Some of these are chemo-
attractants for PMNLs [23]. Interferons, derived from T-cells (IFN-gamma) and from 
monocytes/macrophages (IFN-a) are apparently functionally active in psoriatic skin 
[6,29]. Gamma interferon induces the expression of HLA-DR on keratinocytes [30], 
increases the expression of HLA-DR on Langerhans cells and endothelial cells and 
induces the expression of intergrins. Intergrins are glycoproteins that function as cell 
surface receptors that play a role in the adherence of lymphocytes onto endothelial cells, 
keratinocytes, fibroblasts and dendritic cells [31,32]. All these factors are known to play a 
role in immunologic inflammation in psoriasis. 
Recent investigations on the possible role of dentritic cells in the psoriatic skin suggest an 
important role of these cells in psoriasis [33], which may enable us to find a path in this 
complex labyrinth of data. 
Current therapies 
Topical treatment 
Topical application of drugs is the first choice in the treatment of psoriasis. Especially tar 
preparations, dithranol and corticosteroids are of value as standardized regimes [7,8]. 
A- Tar preparations [34,35]. Coal tar, a product of dry distillation of bituminous coal 
(derivatives: pix lithantracis and solutio carbonis detergens) and wood tar (pix 
liquida) a residue of dry distillation of juniper, pine or birch are a mixture of 
aromatic hydrocarbons. They are used in ointments, shampoos and bath formulati-
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ons and in combination with dithranol (Ingram regimen) or combined with 
ultraviolet radiation (Goeckerman therapy) [36]. 
The effectiveness of these compounds in psoriasis is possibly due to an inhibition 
of keratinocyte mitosis and subsequently of the keratinization process and an anti-
pruritic effect. The tars are potential carcinogens probably due to the induction of 
the mono-oxygenase arylhydrocarbonhydroxylase but at the concentrations used in 
treatment schedules this adverse effect is minimal. Forty-one out of 1585 (2.6%) 
patients treated with tars developed non-melanoma skin cancers during a follow-up 
period of 10-25 years [33]. Other unwanted reactions include irritation, folliculitis, 
phototoxicity and possible contact sensitization [37] or photo contact sensitization. 
These aspects together with the brownish colour and the odour limit the use of 
tars. 
B- Dithranol (1,8 dihidroxy-9-anthrane, syn. cignolin, anthralin) is a yellow, cristalli-
ne powder soluble in ether, benzol, chloroform and paraffin. It is insoluble in 
water. It is soon oxidised and inactivated by light, high temperature, zinc-ions and 
basic pH. Classically, 0.1-3% dithranol in vaseline is applied for 24 hours. The 
dithranol concentration is slowly increased until the desired therapeutic effect is 
obtained [7,8,39]. In the short-contact regimen up to five times higher concentra-
tions are used for 10-20 minutes [39]. The suspected mode of action in psoriasis is 
via suppression of RNA synthesis, inhibition of glycolysis and the suppression of 
mitochondrial metabolism. It is also cytotoxic to the upper epidermal layers [40]. 
The possibility of irritation and the purple coloured oxidation products require 
careful instructions to the patients for optimal compliance. 
C - Glucocorticosteroid hormones for topical application are in use since 1952 and 
available as many different ready-to-use preparations. They can be divided into 
four classes of increasing potency. Esterification and halogenation of the steroid 
molecule provide more potent preparations. For clinical application the area, the 
location and the duration of treatment are relevant for an optimal benefit-risk ratio. 
Plastic occlusion and intralesional injections have a special place in recalcitrant 
psoriatic plaques [7,8,41]. The main mechanism of action is thought to be that 
after penetration, corticosteroids pass through cell membranes to bind to cytosolic 
receptor proteins. The steroid-receptor complex then enters the nucleus where it 
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binds to DNA. This results in an a altered mRNA transcription, which in tum 
stimulates or inhibits specific protein synthesis. The phospholipase inhibitor, 
lipocortine is produced and interleuki.n-1 formation slowed down. Further, the 
immigration of inflammatory cells is reduced, the antigen presentation is inhibited, 
possibly via altered Langerhans cell function [42] which arrests the clonal T-cell 
expansion. Vasoconstriction, inhibition of DNA synthesis and mitosis make them 
potent anti-psoriatic drugs. A rapid (first pass) biotransformation to inactive com-
pounds yields a topical steroid with minimal (unwanted) systemic effects. Local 
adverse effects are athrophy, striae, ecchymoses, infections and perioral dermati-
tis. Tachyphylaxis (acute intolerance) is known [43]. The relapse rate of psoriasis 
after stopping is high and occurrence of severe pustular reactions in this context 
are feared. Moreover systemic effects on the pituitary-adrenal axis are to be 
suspected by transdermal penetration after long-term use. 
Systemic Therapy 
When large areas of the body are involved in psoriasis or in case the disease is resistant 
to topical treatment, the use of other regimens, like ultraviolet radiation, retinoids and 
methotrexate is required. 
A - Ultraviolet light (UV) therapy involves the use of non-ionizing radiation with 
wavelengths between 290 and 400 nm. The light sources used for this therapy 
have a high spectral output in a selected range, UVB (290-320 nm) or UVA (320-
400 nm). Photochemotherapy combines UVA and oral photo-absorbers like 8 
methoxy-psoralen (PUVA) [44]. 
In the skin UV light is absorbed by melanin, tryptophan, tyrosine, nucleic acids 
and photoactive substances and via excitation a range of chemical events is 
initiated. This results in a biological reaction related to skin type and dose and 
includes erythema, pigmentation, thickening of the epidermis, endothelial swelling, 
extravasation of erythrocytes, an increase of prostaglandins, a decrease of interleu-
kin-1, damage of mitochondriae and keratinocyte cell-death. 
The expression of Langerhans cell markers is inhibited and depleted [45]. The 
dermal infiltrate of lymphocytes decreases, possibly as a result of impaired 
interleukin-2 production [46]. Patient selection is important. Caucasians with skin 
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type II-V and an age between 20-60 years show good responses in case of uncom-
plicated forms of psoriasis like the plaque and guttate variant. Testing of the 
minimal erythema dose and careful dosimetry are relevant. Over 80% of the 
patients respond well in 20-40 sessions. With a 2 months maintenance therapy (one 
or two sessions a week) psoriasis can be controlled for 6-12 months. Continued 
use, however includes the potential risk associated with long-term UV-light 
exposure. 
In day care centres, combination of UV A with coal tar (Goeckerman therapy) [47] 
or a psoralen bath can be carried out. PUV A can be combined with topical 
steroids or retinoids (re-PUVA) [45]. Main exclusion criteria for PUV A-therapy 
are abnormal liver functions and cardiovascular disease. Other contra-indications 
for phototherapy are the use of photo-sensitizing drugs, photo-allergy, diseases 
with a known photo-reactivity like lupus erythematosus or herpetic infections and a 
history of treatment with arsenic, ionizing radiation or tumors. 
Side-effects are itching, hyper- and hypopigmentation and long-term effects such 
as premature aging (fragmentation of elastic :Ebres), actinic keratosis to overt skin 
cancer including melanoma [ 45] and in uncontrolled use acute reactions like 
erythema and burned skin. Tumor incidence seems to correlate with the cumulative 
UV dose (J/cm2) and a combination of risk factors like the use of arsenic or tar 
[48]. The side-effects of psoralens (nausea, headache, dizziness and UV sensitivity 
after exposure to the artificial light source) must be added to those of UV therapy 
alone. 
B - Aromatic retinoids. Etretinate and its principal free acid metabolite acitretin are 
synthetic vitamin A (retinol) derived preparations [48-51]. After oral intake, 
retinoids are absorbed from the intestinal tract (maximum 40%), transported by 
albumin and lipoproteins and metabolized in the liver. The main metabolite binds 
to cellular retinoid acid binding protein (CRABP). The long elimination time of 
etretinate is explained by storage in fat tissue [52]. 
The antipsoriatic effect is supposed to be multifactoral and includes the modulation 
of cell proliferation by a decreased mitotic rate. An influence on the keratinization 
process is deduced from an inhibition of the cornified cell envelope synthesis and a 
high number of keratohyalin granules. The modulation of a number of regulating 
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processes takes place such as inhibition of ornithine decarboxylase and reduced 
polyamine synthesis, a higher post-translational glycosylation and production of 
proteoglycans, next to an increase of type II cAMP dependent protein kinase and 
reduced angiogenesis. Immunomodulation and suppression of inflammation occur 
via migration inhibition of polymorphonuclear neutrophils and functional inhibition 
of lymphocytes, macrophages, Langerhans cells and a decrease in IFN production 
and arachidonic acid metabolism [53,54]. Retinoids can be effective especially in 
the pustular and erythodermic variants of psoriasis. A dose of 0.5-1 mg/kld can 
normalize psoriatic skin within 3-6 weeks. Hereafter a maintenance therapy for 3-6 
months is advised. About 6 months later 70% of the patients show a relapse. Forty 
percent are non-responders [55]. Main exclusion criteria are pregnancy because of 
teratogenicity, abnormal liver function and hyperlipidemia. The side-effects are 
muco-cutaneous complaints like erythema, irritation of mucous membranes 
(cheilitis, rhagades, dryness), stickiness and athrophy of the skin, peeling palms 
and soles, alopecia and multiple extra-cutaneous effects such as ophthalmologic 
disorders, liver toxicity, hyperlipidemia and cartilage degradation (preterm ossi-
fication of epiphyseal discs). Effective contraceptive measures are necessary for 2 
years after stopping the drug [55]. 
C- Methotrexate (MTX, amethopterin, 4-amino-4-deoxy-NlO-methylpteroylglutamic 
acid) is a folic acid antagonist. It inhibits dihydrofolate reductase and thus prevents 
DNA synthesis, blocks mitosis and lethally damages epidermal cells and interferes 
with protein synthesis. An inhibitory effect on the immune system has been 
reported [56]. Though intestinal function is relevant for the availability of (oral) 
MTX, blood serum levels are of little value in monitoring the effectiveness. The 
plasma half-time is 2 h. 
About 50% of circulating MTX is bound to albumin. It is excreted by the kidneys 
(50-80% in 24 h) but a high output of alkaline urine is imperative. MTX is used 
for severe or disabling psoriasis and psoriatic arthritis, though there are many 
exclusion criteria. Several intermittent, low oral dose schedules are in use with an 
advised maximum dose of 25 mg per week. After a clearing phase, MTX can be 
continued for more than a year (maintenance period) [7,8]. 
Rebound reactions or tachyphylaxis are not reported. The effect of topical MTX is 
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hampered by a low percutaneous penetration. 
Exclusion criteria for use of MTX are liver or renal dysfunction, pregnancy, 
peptic ulcer, excessive alcohol intake, anaemia, thrombopenia, leucopenia and 
interfering medication. Many side-effects of MTX are known. Subjective com-
plaints include nausae, vomiting, abdominal pain, decreased appetite, fatigue, 
headache, dizziness, loss of libido, impaired memory and in particular hema-
topoietic suppression. Hepato-toxicity (cirrhosis) is monitored by liver function 
tests and liver biopsies. The predictive value of these parameters, however, is still 
under investigation [57,58]. The risk of (skin) malignancies seems only of 
theoretical value. MTX pneumonitis is rare on the low doses used for antipsoriatic 
treatment. Foetotoxicity is only reported in the first trimester of pregnancy [56]. 
Notwithstanding these facts and many contra-indications, MTX is regarded to be a 
safe drug if the "MTX guidelines" are observed [59]. 
Apart from the above mentioned established therapies several new drugs are under 
investigation for psoriasis. Two of the most promising are vitamin D formulations and 
fumaric acid. 
A- The vitamin D calcitriol (la, 25-dihydroxyvitamin D3) and its analogues are under 
investigation for their effects after some cases with hypocalcemia-induced psoriasis 
were published. The skin appeared to be a target organ for calcitriol in addition to 
the intestine and bones, in regulating calcium metabolism. On the basis of in vitro 
studies and preliminary studies in men, this agent should be highly effective on 
hyperproliferative skin diseases. Its suspected mechanism of action is the regulati-
on of the terminal differentiation of keratinocytes and modulation of the dermal 
inflammatory infiltrate. Side-effects are stones in the urinary tract and calcification 
of blood vessels. Topical dosing seems preferable to bypass these effects [60-62]. 
B- Fumaric acid (FA) is used as combination of sodium salts of the mono-ethyl ester 
and dimethyl-ester with or without a diet in the treatment of psoriasis. A deficien-
cy of fumaric acid could not be demonstrated in psoriatics. The mechanism of 
action is possibly an anti-mitotic effect. Recent open and double-blind studies 
showed that oral FA therapy is only effective after about 4 months. Topical 
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treatment with FA formulations showed a low response. FA esters have severe 
side-effects such as flushing, dizziness, fatigue, pain of the upper digestive tract, 
leucopenia (due to a decrease of CDS+ T-lymphocytes) and nephropathy that 
turned out to be irreversible in some cases. Up till now the success of this therapy 
initiated by Schweckensiek (1959) [63] and regarded by the public as a "natural" 
therapy remains unproven. The toxicity and the teratogenic effects have not been 
quantitated as a consequence, the benefit-risk ratio has not been determined as yet 
[64]. 
The action mechanism(s) of all the drugs described above on the metabolic and immuno-
logic aspects of psoriasis cannot be clearly separated but can be divided into three major 
groups: 
1) Influence on metabolic process: tar, dithranol, fumaric acid, calcitriol 
2) Influence on immunologic aspect: steroids, UV 
3) Influences on metabolic and immunologic aspects: retinoids, methotrexate 
On the basis of our current knowledge on the action mechanism(s) of CyA (Chapter 1), 
the drug would best fit in group 2. 
It is too early to conclude which point of intervention, either the metabolic or the 
immunologic will be more effective, irrespective of the question whether this theoretical 
approach is the final truth. 
Aim of the study 
Although a large therapeutic arsenal of conventional drugs is available to treat patients 
with psoriasis, a group of patients still exists that fulfill the inherent exclusion criteria or 
present with subjective or objective side-effects. This necessitates the need for controlled 
studies with potential new antipsoriatic drugs like cyclosporin A. In this thesis patient-
oriented studies on the treatment of severe psoriasis vulgaris with systemic low-dose and 
topical cyclosporin A are presented in an attempt to answer the following questions. 
A - What is the efficacy of short-term low-dose cyclosporin A in patients with severe, 
recalcitrant psoriasis ? (Chapters 3 and 4) 
B - Is there a preferential dose regimen for long-term treatment, either continous or 
intermittent ? Can the combination with a conventional drug like etretinate produce 
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an additive positive effect ? (Chapter 5) 
C- Can topically applied cyclosporin A be effective in dermatologic disorders such as 
psoriasis ? (Chapter 6) 
D - What are the side-effects of orally administered cyclosporin A ? How can nephro-
toxocity be monitored ? What are the recommended guidelines for the practicing 
dermatologist for using cyclosporin A ? (Chapters 7 and 8) 
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Summary 
The effectiveness of cyclosporin A (CyA) in low dosages (mean 5 mg/kg/d) for short-
term treatment of severe psoriasis was studied. Of five patients with severe progressive 
psoriasis vulgaris (mean PASI score 43.8), an almost complete remission in three 
patients, and a large reduction in P ASI score in the remaining two patients, was obtained 
within 4 weeks. No important clinical side-effects were found but there was biochemical 
evidence of slight renal dysfunction in one patient. The mean percentage reduction in the 
PASI score was 84%. The results reported justify further study of CyA in the treatment 
of severe psoriasis. 
Introduction 
In psoriasis a number of aberrations of the immune system have been reported (1]. The 
cellular infiltrate in the clinically active psoriatic lesions may contain 30% activated T 
cells [1] and there is evidence of functional defect in T-lymphocytes [2]. 
CyA may interfere with T-cell functions, i.e. by blockade of the production of interleuk-
ins, in particular interleukin-2 [3]. Apparent responsiveness of psoriatic lesions to CyA 
has been described recently [4]. In a restricted number of patients with renal transplants 
and psoriasis, it has been reported that the skin lesions improved significantly during CyA 
treatment [5,6]. 
We present here a pilot study aimed at determing the effectiveness of a short-term "crisis-
intervention" treatment of four weeks with CyA in five patients. In addition, the response 
to CyA was evaluated during a second period of 4 weeks. 
Methods 
Patients 
Five patients (Table 1) were selected on the following criteria: unequivocal clinical and 
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histopathological diagnosis of chronic plaque form psoriasis, severe disease, long duration 
of disease (mean 27 years) and resistance to conventional anti-psoriatic therapy (topical 
therapy including steroids, systemic therapy with PUVA or retinoids or both). Four 
patients had been treated previously with methotrexate with variable results. 
On entering the study, all the patients exhibited progressive psoriasis with serious physical 
and social disabilities. Patients were excluded from the study if they were pregnant or 
suffering from infection, malignancy, impaired renal function (serum creatinine > 110 
/kmol/1), impaired liver function, uncontrolled hypertension (age 18-50 RR > 150/95, 
age 50-60 RR > 60/100), epilepsy, malabsorption syndrome or drug or alcohol abuse. 
Other criteria for exclusion were: treatment with methotrexate, retinoid or PUV A within 
one month, or topical anti-psoriatic agents within 2 weeks before the start of the trial. 
Clinical evaluation before and during therapy was carried out using the Psoriasis Area and 
Severity Index (PAS I) [7] [Addendum 1]. The P ASI score increases in units of 0.1 from 
0.0 (no lesions), to 72.0 (complete psoriatic erythroderma of the severest possible 
degree). The PASI score was recorded before the start of the trial and at weekly intervals 
during therapy. 
On entering the study all five patients had a PASI score 2.. 28 (mean 43.8) (Table 1). 
CyA (SandimmuneR, 100 mg/ml) was given orally in two daily doses on the basis of body 
weight. Full blood count, renal and liver function and blood pressure were measured at 
weekly intervals. Determinations of trough blood CyA concentrations using a cyclosporin 
RIA-Kit, (Sandoz Ltd, Basel, Switzerland) were performed weekly (Table 2). 
The initial dose of CyA (4.4-6 mg/kg/d) was given for 4 weeks (Table 2). In the second 
4-weeks period (weeks 5-8) the dose of Cy A was gradually adapted for individual 
patients, in particular in relation to the PASI score (Table 2). No other anti-psoriatic 
treatment was given. 
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Results 
The PASI scores in the patients before entering the trial and after 1,2,4 and 8 weeks are 
given in Table 1. The dosages and trough blood concentrations of CyA are given in Table 
2. Mean PASI scores, trough blood CyA concentrations and CyA dosages over weeks 1-4 
are shown in Figure I. 
First treatment period (weeks 1-4) 
A low dose of CyA (mean 5 mg/lcg/d Table 2) had a satisfactory effect in all five patients 
with severe psoriasis [colour plates 1 and 2]. In patient 1 a substantial fall in the PASI 
score was found within the first 2 weeks (53.2-8.4). In patients 4 and 5, within 2 weeks, 
the PASI scores fell by 53% and 40% respectively. The mean PASI score in the five 
patients after 2 weeks was 22.6 compared with 43.8 at start of the trial. The mean PASI 
score fell from 43.8 to 6.1 in the first 4 weeks of the treatment. This represents a mean 
improvement of 84 % . The clinical response by the end of the first 4 weeks was most 
striking in patients 1 and 2 (98% and 97% reduction in PASI score, respectively, Table 
1). 
Second treatment period (weeks 5-8) 
The decision was made to stop CyA in patient 1 during weeks 5 and 6, because of the 
striking remission (PASI score: 0.9). T~is resulted in an acute relapse within one week. 
Thereafter, the psoriasis reacted far more slowly to re-institution of CyA at a dose of 4.7 
mg/kg/d (trough blood level: 530-590 ng/ml) (PASI score at 8 weeks: 10.3; Table 1). In 
patient 4, after increasing the dosage to 7.0 mg/kg/d (Table 2), there was a fall in the 
PASI score from 12.3 (week 4) to 1.3 (week 8). In the second period of 4 weeks the 
mean PASI score did not change substantially; falling from 6.1 to 4. 7. During this period 
of the trial a low dose of CyA was found to be effective, giving excellent results in 
particular in patients 2 and 4. In patients 2, 3 and 4 a substantial improvement occurred 
in psoriatic nail lesions. In patient 4, with severe psoriatic arthropathy, a striking 
subjective and objective improvement was noticed (~40%). 
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Clinical side-effects, including mild reversible hypertension (160/100) (patients 1 and 4), 
and mild intermittent diarrhoea (patient 3), were observed. Clinically important disturban-
ces of renal or liver function or blood count were not seen. Nevertheless, biochemical 
evidence of mild renal dysfunction was found in one patient (patient 4). 
Discussion 
We report here the effectiveness of CyA in crisis intervention therapy in five selected 
patients with severe, chronic and drug-resistant psoriasis. Mueller & Herrmann [4] first 
reported a dramatic response to Cy A within one week in four psoriatic patients but the 
psoriatic lesions gradually returned to their previous severity within 2 weeks after 
stopping CyA. MUller and Graf [8] described four patients who received CyA with a 
striking improvement of severe psoriatic arthritis and of psoriatic skin lesions. These 
authors observed improvement of the arthritis in three out of the four cases and a striking 
reduction of the psoriatic skin lesions in all four cases in the first 2-4 weeks of treatment 
with CyA in high initial doses (about 900 mg/d). Three out of the four cases relapsed 
after the dosage of CyA was reduced 200-400 mg/d. In these studies no measurements of 
the clinical improvement in relation to blood concentrations of CyA were performed. 
In our patients a tendency to a dose dependent response to CyA was seen in patients 1 
and 4. In patient 3 a less striking response was seen (PASI score: 8.0 at week 8) with 
lower trough blood concentrations of CyA (160-250 ng/ml. In patient 5, however, despite 
a very low blood concentration (70 ng/ml at week 8, (Table 2)), the PASI score remained 
low (2.7). 
The number of patients was too small for adequate experiments to determine optimal 
dosages. However, the present study shows that at dosages between 4.7 and 8.1 
mg/kg/d (trough blood concentrations between 390 and 980 ng/ml), short-term therapy 
with CyA is of value as psoriasis "crisis intervention". 
The pharmacokinetic mechanism in psoriasis is still unknown, but it is tempting to assume 
that modification ofT-cell functions by CyA plays a central role in the response to CyA 
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treatment. However, further studies are required to investigate possible inhibitory effects 
of CyA on the abnormal proliferation of keratinocytes in psoriasis. Keratinocytes produce 
a cytokine (epidermal cell derived thymocyte-activating factor) which closely resembles 
interleukin-1 [9]. 
CyA acts in the preliminary phase of the immune response and it has been suggested that 
if long-lived populations of primed T-cells are operative, the beneficial response to the 
drug may become apparent after several months of treatment only [10]. Such a mecha-
nism would explain the incomplete responses in our patients. 
CyA can give rise to a variety of side-effects and, for the present, its use -like that of 
other immunosuppressants- must be contemplated only in severe psoriasis, which is 
physically or socially extremely disabling. Treatment of psoriasis and psoriatic arthritis 
with cytostatic drugs as methotrexate can also evoke a beneficial response within a 
reliable period, but numerous side-effects (in particular of the liver and bone marrow) are 
described [11]. We obtained a mean reduction in the PASI score of 84% after 4 weeks of 
treatment. Fredriksson and Petterson [7] reported a reduction of 63% after 4 weeks' 
treatment with retinoids in a group of 10 patients with severe psoriasis. A few possibili-
ties were considered after the eighth week of treatment: (a) stopping CyA treatment; (b) 
trying a low maintenance dosage for a longer time and, (c) a low maintenance dosage of 
CyA in combination with other anti-psoriatic treatment. In our patients we decided after 
the eighth week to continue a low maintenance dose of CyA with no other treatment and 
further individual decreases in dosage, but maintenance of blood concentrations of 2. 200 
ng/ml. In patients 2 and 4, therapy with mean dose of 4 mg/kg/d was continued for a 
further 5 and 12 weeks respectively and was then stopped (PASI score in both cases was 
0 at this point). In patient 2 the PASI score remained 0 two months after stopping CyA, 
without any other therapy. Patients 1 and 5 continued CyA therapy on a low dose 
regimen. In patient 3 (P ASI score of 8 at week 8) the P ASI score was reduced nearly to 0 
after 10 further weeks on CyA at a dosage of 4.5 - 5.5 mg/kg/d (trough blood concentra-
tion ;::: 200 ng/ml). In this case, however, a local relapse of the skin lesions on the hands 
occurred when the dose of CyA was reduced below 4 mg/kg/d. 
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The results of the present study would appear to justify a further placebo-controlled 
double-blind study on the use of CyA in severe psoriasis. The design and the results of 
this study are described in Chapter 4. 
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Table'l. Reductions in PASI* scores in five patients with severe progressive psoriasis vulgaris, treated with 
cyclosporin A 
PAS! score P ASI score after treatment for: Reduction in PASI-score 
Age before P ASI score after after treatment 
Patient no. Sex (years) treatment 1 week 2weeks 3weeks 4weeks 4weeks(%) for8weeks 
1 M 51 53.2 23.5 8.4 4.7 0.9 98 10.3** 
2 M 73 32.3 29.8 26.4 12.0 0.9 97 1.1 
3 M 55 58.0 43.2 36.5 13.2 10.0 83 8.0 
4 F 48 28.2 13.8 13.5 12.6 12.3 57 1.3 
5 F 40 47.5 34.8 28.4 18.0 6.5 86 2.7 
Mean 53 43.8 29.0 22.6 12.0 6.1 84 4.7 
* P ASI =Psoriasis Area and Severity Index (Fredriksson & Petterson, 1978). 
** Cyclosporin not given in weeks 5 and 6. 
Table 2. Doses of cyclosporin A (mg/kg/d) and trough blood levels (ng/ml) (in parentheses) in five patients 
with severe progressive psoriasis 
Weeks 1-4 Weeks 5-8 
Patient no. 2 3 4 5 6 7 8 
1 6 (600) 6 (720) 4.7 (770) 4.8 (890) * • (120) * • ( 60) 4.7 (530) 4.7 (590) 
2 5.6 (700) 5.6 (670) 5.6 (650) 4.4 (610) 4.4 (610) 3.9 ( -) 3.6 ( -) 3.6 ( -) 
3 5.7 ( -) 5.7 (390) 5.7 (430) 5.0 (450) 5.0 (480) 5.0 (520) 4.3 (250) 4.3 (160) 
4 5.5 (530) 5.5 (460) 5.5 (490) 5.5 (430) 7.0 (410) 8.1 (370) 8.1 (750) 7.4 (980) 
5 5.0 (210) 5.0 (210) 5.0 (250) 5.0 (250) 5.0 (240) 4.4 ( -) 4.4 (170) 4.4 ( 70) 
Mean 5.6 (510) 5.6 (530) 5.3 (518) 4.9 (526) 5.4 (372) 5.4 (317) 5.0 (400) 4.9 (450) 
** In Case 1 cyclosporin was stopped during weeks 5 and 6 (see text). 
- = Not estimated. 
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FIGURE r. Mean CyA dose, trough blood CyA level and PAS! score in five patients with severe psoriasis. 
• Mean PAS! score; 0 mean trough blood level of CyA (ngiml); "-mean dosage of CyA. 
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Summary 
Twenty patients with severe plaque psoriasis were selected to receive either low-dose 
cyclosporin A (CyA) or placebo (CyA vehicle) in a double-blind randomized trial at two 
centers. Within 4 weeks the mean reduction in the Psoriasis Area and Severity Index 
(PASI) in 10 patients receiving CyA (mean dose 5.5 mg/kg/d) differed significantly from 
the mean reduction !n 10 patients receiving placebo. In eight patients given placebo a 
switch to CyA therapy resulted within 4 weeks in a mean reduction in PASI of 90%. In a 
total of 15 out of 18 patients given CyA (83%) (mean dose 5.6 mg/kg/d) there was an 
improvement of 2._ 75% in PASI within 4 weeks. In a 2-month tapering off phase a lower 
mean CyA dose (3 mg/kg/d) was effective in maintaining the reduced PASI scores in 
eight of nine patients. Four out of five CyA treated patients who entered a post-treatment 
observation phase had a relapse (PASI score 2._ 50% of score at baseline) after a mean 
interval of 6.5 weeks. 
The most important side-effects were mild reversible hypertension in 5 of 18 patients 
(28%), and reversible elevated serum creatinine levels in 7 out of 18 patients (39%). We 
consider that further studies are justified in severe chronic psoriasis to establish suitable 
regimes for maintenance of remission in psoriasis with low doses of CyA or a combina-
tion of CyA with other anti-psoriatic agents. 
Introduction 
CyA selectively influences the function of lymphocyte subsets [1,2]. In a number of 
dermatologic conditions [3,4], over the past few years CyA has been used with more of 
less effects. In the treatment of psoriasis it is evidently a potent drug. Initially some case 
reports mentioned a remission of concomitant psoriasis when CyA was used in arthritis 
[5] or organ transplantation [6,7]. By that time the dosage schemes were high, namely 10 
to 14 mg/kg/d. Later on open trials have demonstrated that lower dosages of 3 to 5 
mg/kg/ d have a significant beneficial effect in severe recalcitrant psoriasis [8-1 0]. A 
double-blind study [11], with a high-dose regime (14 mg/kg/d) showed that CyA was 
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significantly better than the placebo drug. We conducted a double-blind study in two 
academic hospitals in 20 patients with chronic plaque-form psoriasis of a therapy-resistant 
character. 
In phase 1 (weeks 1 to 4) low-dose CyA was compared to placebo to study the efficacy 
to induce a remission of the disease. 
In phase 2 (weeks 5 to 12) a stepwise tapering of the CyA dose in responders was 
performed to determine the lowest effective dose necessary to maintain the improvement 
or to prevent an exacerbation. 
In phase 3 (weeks 13 to 24) CyA therapy was stopped to study the interval till recurrence 
of complaints. 
Methods 
Selection of Patients. In each of the two centers, ten patients were selected: 13 females 
and 7 males. Inclusion criteria were a clinical and histologic diagnosis of chronic plaque 
psoriasis of a progressive character, over more than 10 years (Table 1). 
Conventional therapy, eg, topical steroids, PUV A, oral methotrexate, or retinoids, singly 
or in combination, had been given with no or only temporary effects. Patient ages were 
between 20 and 70 years. Exclusion parameters were pregnancy or acute uncontrolled 
infection, either bacterial, viral or fungal, as well as impaired renal function with a serum 
creatinine over 100 ,umol/1, bilirubin or liver enzymes more than twice the upper limit of 
the normal range, uncontrolled hypertension (ages 18 to 50 years BP 150/95 mmHg; ages 
50 to 60 years, BP 160/100 mmHg), other diseases such as epilepsy, malabsorption 
syndrome, and past or present malignancies, and intoxication with abused drugs, alcohol, 
nephrotoxic drugs (e.g. amino glycosides or nonsteroidal anti- inflammatory drugs), and 
drugs known to affect the pharmacokinetics of Cy A (ketaconazole, erythromycin, 
phenytoin, phenobarbitone, rifampicin, isoniazid or carbamazepin). 
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Active antipsoriatic treatment were stopped: methotrexate, retinoids or PUV A four weeks 
and topically applied agents two weeks before start of the trial. 
Clinical evaluation 
Improvement or worsening of the skin condition was analyzed with the Psoriasis Area and 
Severity Index (PASI) [12] (Addendum 1). This score system increases in units of 0.1 
from 0.0 (no lesions) to 72.0 (complete psoriatic erythroderma of the severest possible 
degree). All patients started with a PASI of 20 or above. 
Phase 1 
Twenty patients were randomly treated with CyA of placebo during 4 weeks, in a double-
blind set up. They were hospitalized for this period. CyA (SandimmuneR, Sandoz Ltd. 
Basel, Switzerland) 1 ml solution contains 100 mg CyA powder or placebo (the vehicle 
consisting of olive oil and polyethylated oleic glycerin) was given in two equal daily 
doses (at 8:00 AM and 8:00 PM). 
Daily doses were adjusted on the basis of body weight: < 59 kg, 3 ml; 60 to 80 kg. 4 
ml; > 80 kg, 5 ml. The doses were reduced according to protocol by 1 ml if an 
unwanted change in criteria was noticed: (1) serum creatinine value rose above the 
baseline of 60 ~mol/1, [13]; (2) serum potassium rose above upper limit of normal range; 
(3) an increase of serum bilirubin or liver enzymes above twice the upper limit of normal 
range; (4) hypertension unresponsive to antihypertensive therapy; or (5) whole blood 
trough levels of CyA above 900 ng/ml (reported by the nonblind investigator). 
If the abnormal values did not normalize within 2 weeks, the CyA dose was further 
reduced by 1 ml. The test medication was withdrawn when these measures had no result 
or when subjects developed symptoms of infection. 
Nonresponders were defined as patients who had a reduction in PASI of less than 50% at 
week 4 compared to their score at the start of the trial. When the test medication was 
stopped, the code was broken. Patients who had received placebo were switched to CyA 
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treatment in an open outpatient trial with the same dose schedule of Cy A as in phase I. 
Phase 2 
The patients who responded with an improvement of more than 50% at the end of week 4 
received the test medication for another 2 months (weeks 5 to 12) in a double-blind way. 
During this period the doses were reduced at two weekly intervals according to the 
schedule in Table 2. An increase of the P ASI during the tapering process to a value equal 
or above 50% of the baseline value (before therapy) was called a relapse situation. When 
this happened the test medication was stopped and an alternative therapy was chosen. 
Phase 3 
Posttreatment observation period of 3 months. Cy A treatment was stopped. Those who 
consented to receive no other antipsoriatic medication entered phase 3. If a relapse 
occurred patients were excluded. The P ASI was measured monthly. 
During phases 1 to 3 creatinine and potassium were measured at weekly intervals. Blood 
pressure, bilirubin and liver enzymes, urine analysis, and full blood count were measured 
every 2 weeks. Trough blood CyA concentrations 10 to 14 hours after the last dose of 
CyA were measured using the CyA RIA-Kit (Sandoz). Measurements were made at 1-
week intervals in phase 1 and at 2-week intervals in phase 2. 
Statistical analysis was performed using the Mann-Whitney U test to compare the 
changes in PASI values (score at the end of week 4 minus score at baseline). The same 
test was used to evaluate the blood pressure (systolic/diastolic) and creatinine values. The 
differences in the values of the period from week 0 to 4 were compared to the differences 
of weeks 0 to 4 in the CyA-treated and untreated groups. Changes within both treated and 
untreated groups of blood pressure and creatinine data (week 0 v weeks 4, 12, and 24) 
were assessed by the signed rank test (SRT). 
Results 
The doses and PASI value in patients receiving CyA are summarized in Fig. 1 and Tables 
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3 and 4. 
The CyA dosage of patient 10 in week 2 and patient 2 in week 3 was reduced because the 
blood levels exceeded 900 ng/ml. This was not due to an overdose but appeared to be 
peak levels. A consistent relationship between the clinical response and Cy A blood levels 
could not be found. 
Phase 1 
After the initial period of 4 weeks (phase 1) the number of nonresponding patients was 
11. Their code was unsealed and all but one (patient 6) appeared to have received 
placebo. At the end of week 12 the code of the responders was broken; they all had 
received CyA. The mean percentage reduction in the PASI score at the end of week 4 in 
the group treated with Cy A (72%) was significantly greater than the mean percentage 
reduction in the placebo group 3% (p < .001). In four patients in the placebo group 
(patients 13, 15, 17 and 19) worsening of the psoriasis was seen during phase 1. 
The patient (patient 6) that did not react well (nonresponder) at week 4 improved on a 
higher dose of CyA after another 4 weeks (percentage reduction of PASI 79%). A slow 
reaction was seen in patient 7, who accidentally had received a lower dose of CyA (4 
ml/d - 4.3 mg/kg/d) that did not correlate with his body weight (93 kg). 
Phase 2 
The mean percentage reductions of PASI in week 12 compared to the baseline values (for 
n = 9) was 82%. This means a further improvement of 10% (PASI reduction week 4, 
72%). All nine patients had received CyA. In one patient (patient 2) a relapse was 
observed during week 12 (Table 4). In these nine patients a substantial improvement was 
observed in psoriatic nail lesions. The mean CyA dose during this tapering-off phase 
(weeks 5 to 12) was 3 mg/kg/d with mean CyA whole blood trough levels of 317 ng/ml. 
The mean CyA dosage during weeks 11 and 12 even went down to 1.4 mg/kg/d, which 
gave a mean blood level of 131 ng/ml. 
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Phase 3 
At the start of this (posttreatment) phase of the trial, three of the remaining eight patients 
insisted on either continuation of CyA therapy Oow-dose) or an alternative antipsoriatic 
therapy modality. Thus, only five patients entered phase 3 of the trial (Table 4, Fig lC) 
In two patients a relapse was seen at week 16 (patients 7 and 9) two patients had relapsed 
at week 24 (patients 3 and 8), and one patient maintained a PASI of 2.1 (patient 1). It is 
worth mentioning that this last patient had the habit of taking a spoonful of cod liver oil 
every day. 
Switch to Cy A therapy in the placebo group 
Eight patients of the placebo group wished to take part in the CyA treatment procedure. 
The other two (patients 14 and 20) preferred to receive an alternative treatment. The 
mean percentage reduction in PASI of those who received CyA treatment (mean dose 5.7 
mg/kg/d) was 90% after 4 weeks when compared with PASI at the and of 4 weeks on 
placebo (Table 5 and Fig lB). 
Adverse effects 
In none of the patients was the CyA dose reduced because of clinical, haematologic, or 
biochemical side-effects. The clinical side-effects in the total of 18 patients receiving CyA 
were aching muscles (5), fatigue (2), headache (1), mild painful gynecomastia (one male), 
tremor (1), gastrointestinal upset (1), development of mild hypertrichosis (two males), and 
verruca vulgaris (1). 
The increase of the systolic blood pressure in the first 4 weeks of Cy A treatment (patients 
1 to 10), compared to the value of the placebo patients in the same period (patients 11 to 
20) was significant (p = .03), but such a significant difference could not be recorded for 
the diastolic blood pressure. The shift of the systolic blood pressure within the CyA-
treated group of periods 0 to 4 weeks, 0 to 12 weeks, and 0 to 24 weeks was significant 
(SRT) with p values of .03, 0.3, and .05, respectively, whereas the diastolic blood 
pressure did not show significant differences (Table 6). The increase of the serum 
creatinine in phase 1 of CyA-treated patients compared to the change in creatinine of 
placebo patients was not significant (p = .08). The creatinine values at weeks 4 and 12 
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within the CyA group did not differ significantly. In period 0 to 24 weeks, on the other 
hand, the increase proved to be significant (p = .0.5, SRT) (Table 6). This was less than 
40% above their respective individual baselines. In all patients the serum creatinine level 
rapidly returned to normal when the CyA dose was reduced (phase 2) or stopped. 
Discussion 
With CyA an almost complete remission of recalcitrant psoriasis was obtained within 4 
weeks in 4 out of 18 patients (22 %) with a low mean dose of 5.6 mg/kg/d, while in 15 
(83%) an impressive amelioration (reduction in PASI of 75%) was seen (Table 7). These 
results of low-dose CyA are significantly better than placebo. In view of the relatively 
minimal side-effects, CyA represents an advance in the short-term treatment of psoriasis. 
In general it can be concluded that the oral dose of CyA (mg/kg/d) is a more important 
hallmark for therapeutic results than the measurements of whole blood trough levels. 
The difference observed in the improvement of the group that received CyA initially 
(mean percentage reduction in PASI score after 4 weeks 72%) and of the group that 
switched from placebo to CyA (mean percentage reduction in 4 weeks 90%) might be 
mainly explained by two reasons: the existence of a varying sensitivity of psoriasis to 
CyA in individual cases and the different character of that part of the study (open and 
out-clinic setting). In one patient (patient 6) there was a reduction in PASI of less than 
50%. This patient, however, had an excellent response when the CyA dose was increased 
to 6 mg/kg/d. 
The experiences m our center and of Ellis et al. [11], learn that low-dose CyA (5 
mg/kg/d) has little or no effect in patients with active guttate psoriasis, especially when 
triggered by bacterial infections. A case of recalcitrant psoriasis pustulosa (Von Zum-
busch type), which responded to a much higher dose of CyA, has also been published 
[14]. Additional conclusions can be drawn with regard to the efficacy of low-dose CyA. 
During the tapering off phase a further clinical improvement was seen at doses between 2 
and 3 mg/kg/d. In a recent open trial [10], clearance of psoriasis was observed in a 
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period of 2 to 12 weeks (mean 7.4 weeks) at doses between 1 and 5 mg/kg/d (mean 3.3 
mg/kg/d). These data and ours demonstrate that 3 mg/kg/d represents a critical effective 
CyA dose in certain sub-groups of patients with chronic plaque psoriasis. 
In phase 3 of the trial it was difficult to maintain a treatment-free regimen. Three patients 
preferred additional treatment (drop-outs), because they had developed new lesions on 
hands and face. Four patients continued without CyA. Two of them had a relapse in week 
16, another two in week 24. One patient (patient 1) remained symptom-free even 3 
months after stopping CyA. It can thus be concluded that the relapse time differed very 
much among individuals (mean time to relapse 6.5 weeks) (see colour plate 3). This last 
patient (patient 1) had the habit, since his youth, to take fish oil daily. In itself this diet 
regimen may have an influence on psoriasis, as fish oil contains large amounts of 
arachidonic acid and also some eicosapentaenoic acid [15]. The intake of dietary polyun-
saturated fatty acid may well potentiate the effect of CyA. This intriguing observation 
needs further investigation. 
The side-effects that were observed were no reason to adjust the Cy A dose. The diastolic 
blood pressure did not show a significant increase, neither within the CyA-treated group 
nor compared with the placebo group. The nonsignificant change in creatinine (in phase 
1) may be caused by the small number of patients. The p value, however, points to a 
possible real difference. All the mild clinical and biochemical adverse . reactions norma-
lized during or shortly after phase 3. 
The proven influence of Cy A prompted to investigate the composition of the infiltrate in 
psoriasis skin more thoroughly. CyA may interfere with T cell functions, by interference 
with interleukins, in p<1-zticular with interleukin-2 [16]. The striking response of severe 
psoriasis to low dosages of CyA could be considered a powerful argument for an essential 
role of T cells is psoriasis [17-19]. An additional immunological explanation for the 
effectiveness of CyA in psoriasis might be that the drug interferes with the antigen 
presenting capacity of dendritic cells [20,21], especially in view of the presence in vivo of 
relatively large numbers of dendritic cells bearing Langerhans cell and interdigitating cell 
immunophenotypes in psoriasis [19]. It has been reported that CyA does not inhibit 
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epidermal cell growth [22]. However, abnormal keratinocyte proliferation in psoriasis can 
be induced by epidermal growth stimulating factors liberated by inflammatory cells. This 
release might be inhibited indirectly by CyA due to its effects on T-cells [23,24]. Of 
interest are observations indicating that even after a short period, 3 to 7 days, of high-
dose CyA treatment, the epidermal mitotic activity in psoriatic skin is decreased signifi-
cantly [11]. This observation fits in with our finding that within 2 weeks of treatment with 
low-dose CyA, reductions in PASI score of 50% or more can be obtained. 
We have suggested that low dose CyA might be of use in limited courses for the 
treatment of severe episodes of psoriasis ("crisis intervention") [8]. In that study, it was 
shown that slightly increased serum creatinine levels normalized again after withdrawal of 
CyA. However, additional monitoring of the glomefJ.!lar filtration rate is needed in further 
prospective studies in larger groups of patients to arrive at an optimal regimen for CyA 
therapy in psoriasis. If we can limit serious side-effects, low-dose CyA therapy could 
have an important place in maintaining clearance of or improvement in severe psoriasis 
for longer periods. 
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Table 1. Background data of cyclosporin A and placebo patient groups as determined atthe start of the study 
Cyclosporin A 
patient trial sex age duration of weight(kg) 
no. no. (year) disease (year) weekO 
1 2 male 65 16 66 
2 4 male 62 43 64 
3 5 male 42 17 59 
4 6 female 67 11 77 
5 9 male 63 54 71 
6 21 male 58 50 59 
7 22 female 62 21 93 
8 25 male 30 11 86 
9 26 male 30 13 64 
10 30 male 67 36 63 
N = 10 m/f ratio = 8/2 mv: 54.6 27.2 70.2 
Placebo 
patient trial sex age duration of weight(kg) 
no. no. (year) disease (year) weekO 
11 1 male 53 44 85 
12 3 female 44 17 84 
13 7 male 29 10 60 
14 8 male 40 10 71 
15 10 male 26 3 74 
16 23 female 60 48 75 
17 24 female 49 36 70 
18 27 female 75 4 68 
19 28 male 39 21 81 
20 29 female 59 34 58 
N=lO mlf ratio = 5/5 mv: 45.6 22.7 72.6 
m/f = male over female ratio 
mv = mean value 
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Table 2. Tapering off schedule for the dosage of CyA (ml/d)* during week 5-12 of the trial varying 
dependant on the individual dose in ml/d at the end of week 4. 
Tapering off Cy A 
(Phase2) 
DoseofCyAinweek 5& 6 
DoseofCyAinweek 7 & 8 
DoseofCyAinweek 9&10 
DoseofCyAinweek 11 & 12 
* 1 ml contains 100 mg CyA. 
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3 
2 
2 
Daily dosage ofCyA (mild) 
at end week 4 (phase 1) 
4 
3 
2 
2 
5 
4 
3 
2 
Table 3. Doses of cyclosporin A (mg/kg/d)* whole blood trough levels (ng/ml)** in 10 patients with severe psoriasis 
phase 1 phase2 
week 1 2 3 4 5and6 7and8 9and10 lland 12 
Patients * ** * ** * ** * ** * ** * ** • ** * ** 
p 1 6.1 400 6.1 610 6.1 490 6.1 530 4.5 610 3 290 3 220 1.5 .,;:: 60 
P2 6.3 940 6.3 1060 5.6 750 5.6 250 4.7 700 3.1 590 3.1 250 1.5 260 
P3 5.1 230 6.8 290 6.8 400 6.8 670 5.1 1730 3.3 60 3.3 210 1.3 n.d. 
P4 5.2 710 5.2 460 5.2 480 5.2 410 3.9 350 2.6 130 2.6 80 1.3 < 60 
P5 5.6 430 5.6 430 5.6 310 5.6 350 4.2 350 2.8 180 2.8 180 1.4 90 
co P6 
0 
5.1 539 5.1 584 5.1 347 5.1 702 *** 
P7 4.3 680 4.3 544 4.3 801 4.3 n.d. 4.3 751 3.2 862 2.1 60 1.1 < 60 
P8 5.8 907 5.8 824 5.8 1190 5.8 1020 4.7 778 3.5 n.d. 2.3 n.d. 1.2 < 60 
P9 6.3 451 6.3 450 6.3 867 6.3 n.d. 4.7 309 3.1 250 3.1 263 1.5 < 60 
p 10 6.3 1085 4.8 567 4.8 n.d. 4.8 1720 4.7 n.d. 3.2 524 3.2 571 1.7 305 
Mean 
values 5.6 637 5.6 582 5.6 596 5.6 562 4.5 3.1 2.8 1.4 
mean dose (for n = 10) = 5.6 mg/kg/d mean dose (for n = 9) = cv 3 mg/kg/d 
** Cyclosporin RIA-Kit (Sandoz Ltd, Basel, Switzerland) 
CyA blood cone. 900 ng/ml were peak levels 
n.d.: CyA blood cone. not measured 
*** P 6 = non-responder (see Table 3 and text) 
Table 4. Reduction in PASI in 10 patients with severe psoriasis treated with cyclosporin A (study phase 1-3) 
PASI (study phase 1) %reduction (studyphase2) %reduction (study phase 3) 
baseline end of week: PASI endofweek: PASI end of week: 
Patients to baseline to baseline 
(n = 10) before start 1 2 3 4 4wk 6 8 10 12 12wk 16 20 24 
PI 29.7 24.5 16.2 7.2 6.0 80% 3.9 3.9 2.1 0.4 99% 2.1 2.1 2.1 
P2 34.0 17.9 12.1 10.9 12.2 64% 11.5 10.7 15.6 22,4R 34% relapse in week 12 
P3 42.8 37.3 12.8 11.0 9.9 77% 1.4 0.8 4.0 4.0 91% 8.3 13.1 27.1R 
P4 42.2 23.6 14.9 8.4 7.2 83% 5.2 3.0 7.8 6.8 84% d.o. 
P5 51.5 46.6 20.1 17.8 12.2 76% 2.4 4.0 6.0 6.0 88% d.o. 
P6 21.4 22.2 20.1 18.9 17.5 18% * 
00 
..... P7 52.5 32.0 26.6 28.6 17.2 67% 7.8 7.2 9.0 15.4 71% 27.8R 
P8 43.0 13.5 6.0 6.6 4.1 90% 1.9 n.d. n.d. 1.5 97% 2.6 15.3 26.4R 
P9 19.6 18.2 10.0 4.3 4.0 80% 1.6 1.6 2.4 4.7 76% 16.5R 
p 10 28.4 30.4 14.6 6.1 5.8 80% 2.8 2.6 1.8 1.3 96% d.o. 
Mean 
values 36.5 26.6 15.3 11.9 9.6 72%** 6.9 82% 
mean values for n = 10 mean values for n = 9 
P6 = non-responder 
** : Excluding patient 6, percentages reduction in the P ASI to baseline is 79% 
R : Relapse;;, 50% ofP ASI baseline value 
n.d.: P ASI not performed 
d.o.: drop out: patient unlikely to comply prescriptions 
Table 5. Initial PASI scores and percentages reduction in PASI in 8 of 10 patients switching from placebo (weeks 1-4) to CyA treatment (weeks 1-4) 
Placebo: weeks 1-4 Cy A: weeks 1-4 (mean dosage 5. 7 mglkgld) 
%reduction PASiendof %reduction 
Patients PAS! PAS! week4 PASI PASito mean dosage 
(n = 10) (baseline I) to baseline I (baseline II) endofweek4 baseline II (mglkgld) 
Pll 50.2 11% '44.5 5.0 89% 5.9 
p 12 26.2 21% 20.8 4.8 77% 6.0 
p 13 26.1 - 7% 28.0 0 100% 5.7 
p 14 21.8 28% 15.6 d.o.* 
():) 
[\..) p 15 22.0 -36% 30.0 0 100% 5.4 
p 16 22.4 6% 21.0 3.0 86% 5.3 
P17 52.2 - 1% 52.7 1.8 97% 5.6 
p 18 28.0 7% 26.0 1.6 94% 5.8 
p 19 30.2 -12% 33.8 . 7.4 78% 6.2 
p 20 21.2 14% 18.2 d.o.* 
Mean values 30.0 -3% 29.1 3.0 90% 5.7 
mean values for n = 10 mean values for n = 8 
* d.o. = drop outs (P 14 and P 20) were unlikely to comply further prescriptions 
00 
w 
Table 6. Serum creatinine, min-max (mean), values in J.tmol/1 during cyclosporin A 
(week 0-24) and placebo (week 1-4) 
week 
CyA 
Placebo 
0 
54- 97 (77. 5) 
55-106 (80.0) 
4 
70-94.0 (81.6) 
51-99.0 (77.8) 
12 24 
66-96 (84.4) 69-94 (81.9) 
Bloodpressure. Systolic and diastolic, min-max (mean), pressure values in mmHg during cyclosporin A 
(week 0-24) and placebo (week 1-4) 
Systolic blood pressure 
week 0 4 12 24 
CyA 105-160 (130.5) 115-170 (143.9) 110-160 (143.8) 125-180 (152.9) 
Placebo 120-150 (135.0) 100-155 (133.0) 
Diastolic blood pressure 
week 0 4 12 24 
CyA 70-90 (80. 5) 65-105 (88.3) 70-95 (83.8) 80-110 (90) 
Placebo 75-90 (82.0) 60-110 (82.5) 
Table 7. Clinical response. I. In all CyA recipients (N=18) after treatment for 4 weeks. 
II. To CyA in patients (N=9) after the tapering off period (weeks 5-12) 
I II 
Clinical response based on after 4 weeks Cy A after 12 weeks Cy A 
the P ASI reduction(%) N = 18 N=9 
91-100% 4 ( 22%) 4 ( 45%) 
75- 90% 11 ( 61%) 3 ( 33%) 
51- 74% 2 ( 11%) ( 11%) 
25- 50% 1* ( 6%) 1** ( 11%) 
0- 24% 0 0%) 0 ( 0%) 
Total of patients N = 18 (100%) N = 9 (100%) 
Mean dosage of Cy A week1-4: 5.6mg/kg/d week5-12: N 3mg/kg/d 
P6, see text and Table 3 
** P2, see text and Table 3 
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This chapter is mainly based on the following manuscript: 
Three long-term regimens with cyclosporin for psoriasis vulgaris. 
Reule F, Bousema MT, Laeijendecker R, van Joost Th. Acta Derm Venereol (Stockh) 
1989; 146: 171-5. 
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Summary 
Nineteen patients with severe plaque type psoriasis were selected and divided in three 
groups to evaluate different long-term treatment programmes with cyclosporin A (CyA) 
(up to 130 weeks). Group 1 received a continuous treatment and group 2 an intermittent 
treatment on a low dose. The clinical results proved to be comparable, the side effects 
however were less. Group 3 received a combination of CyA and TigasonR, but TigasonR 
did not show an additional beneficial effect. 
The continuous and intermittent, long-term regimes constitute a well-balanced approach 
for CyA treatment in psoriasis, next to the short-term treatment which we described 
before. 
Introduction 
Cyclosporin A (CyA, SandimmuneR) is increasingly used to treat psoriasis vulgaris. In 
severe attacks and used for a short time (1-3 months) its therapeutic effect is clear 
[1,2,3]. In therapeutic doses the main side-effect, nephrotoxicity, seems to be reversible. 
However, psoriasis shows remissions and exacerbations that pose intricate questions 
regarding monitoring CyA during longer periods [4,5,6]. This study evaluates three 
different approaches with the aim to optimize drug effectiveness with minimal side effects 
over a longer period of time (mean time 58 weeks for 19 patients) than has hitherto been 
studied. 
Patients en methods 
From our earlier studies [1,2] with patients who had a chronic plaque form psoriasis of a 
severe character, 19 patients chose to go on with CyA treatment (Informed Consent was 
given). The selection criteria had been very strict (no pregnancy, renal or liver disease, 
uncontrolled infections, malabsorption syndrome and addiction to alcohol or drugs) and 
were revised for renal or liver disease and hypertension. 
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Besides psoriasis, the following concomitant diseases were present: ulcus duodeni (1), 
diabetes mellitus (2) and CARA (2). Three patients had a history of tuberculosis, now 
confrrmed by X-ray to be silent. They all received isoniazide (INH) prophylaxis. 
Analgetics were allowed for severe (psoriatic) arthropathy. 
The 19 patients were treated with CyA (at random by a blind investigator). In retrospect 2 
main groups could be formed; Group 1 (n =9, see Table I) received a continuous 
treatment with CyA and group 2 (n=lO, see Table I) received an intermittent treatment. 
When a dosage of 5 mg/kg/ d was not able to suppress psoriatic disease below P ASI level 
::;;5 in groups 1 or 2, in 50% of the episodes TigasonR (etretinate, see Chapter 2) was 
added to the CyA prescription (group 3). 
General procedure. The initial attack was treated with CyA to gain a remission. The 
severity of the skin disease was scored with the Psoriasis Area and Severity Index (P ASI) 
(Addendum 1). The dosage used to induce a remission in about 5 weeks was 5 mg/kg/d 
in 2 equal oral doses of a solution containing 100 mg/ml CyA, with individual 
adjustments. 
A remission (R) was defmed as an improvement of the clinical state when PASI becomes 
equal to 5. This means an improvement of ;;;:::; 80% in most cases. The period of time to 
reach this level is called the Remission Induction (RI) time. When the clinical conditions 
remained good (and PASI ::;; 50% of the initial value) a time lapse was passed which was 
called the maintenance (M) period. 
When PASI reached a value over 50% of the initial value, an exacerbation (E) began. 
Each exacerbation was treated as in the initial period. 
Procedure in group 1. The starting dose was diminished to the lowest possible level to 
maintain PASI ::;; 5. Dose adjustments were an increase of the dose when PASI ;;;:::; 5 or 
when an exacerbation occurred. On the other hand, a decrease was effectuated when 
P ASI ::;; 5 or when serious side effects took place. 
Procedure in group 2. Conform group 1 a remission was induced. Then the CyA dosage 
was weaned off to zero and a CyA-free period followed. Only when the clinical situation 
aggravated and the E-point was passed, CyA was prescribed again. In this way each 
episode of activity was handled. 
Procedure in group 3. In groups 1 and 2 six periods were treated with CyA in 
combination with TigasonR (20-40 mg/d) to induce a remission. Anamnestic TigasonR-
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resistance was no reason to withhold this therapy. 
Safety parameters and side effects. Serum creatinine over 130 ,umol/1 was considered to 
be a sign of nephrotoxicity. The upper limit of normal alkaline phosphatase was 75 U/1. 
Platelet counts that passed 320 x 109/1 were considered as reactive. Hypertension was 
defined as a diastolic pressure over 95 mmHg. The patients were seen weekly in the out-
clinic, in the first 3 months of the trial, later on once very month. 
Results 
Group 1. In this group 9 patients were treated during 19 episodes of active psoriasis: 16 
. 
on CyA only, 3 on CyA + TigasonR (see group 3) (Tables II and IVa). In patients on 
CyA, 13 exacerbations were brought into a remission with very good result (PASI :::;; 5) 
in a mean time of 5.9 weeks with 5.2 mg/kg/d CyA. This resulted in a mean maintenance 
time of 24.3 weeks on 3.7 mg/kg/d (n=ll). Three exacerbations (in 3 patients) did react 
with an effect < 65% on 5.8 mg/kg/d CyA in a mean time of 4.5 weeks. 
Group 2. The 10 patients of this group got a treatment during 27 episodes: 24 on CyA 
only, 3 on CyA plus TigasonR (see group 3) (Tables III and IVb). Of 24 episodes on 
CyA, 19 had a very good result (PASI :::;; 5) in a mean time of 5 weeks with 5.5 mg/kg/d 
CyA. The maintenance time had a weaning period of 6.9 weeks on 3.2 mg/kg/d and CyA 
could be stopped for 16.5 weeks until the E-point was passed. Five exacerbations showed 
an effect < 65% in 9 weeks on 4.7 mg/kg/d. When groups 1 and 2 were compared 
considering RI time and doses, there was no substantial difference. Maintenance times of 
group 1 and group 2 were 24.3 and 23.4 weeks, respectively, when weaning period and 
CyA-free period in group 2 were combined. These results were reached with comparable 
doses (Table IV). RI1 , RI2 and RI3 are analyzed in groups 1 and 2 and in comparison 
showed that in the course of time slightly less CyA (25%) was used for the same clinical 
result. This, however, led to a longer RI time (60%). 
Group 3. In this category 2 patients from group 1 (3 episodes) and 2 patients from group 
2 (3 episodes) were treated on the combination therapy (Table IV a and b). The 
representatives of group 1 in group 3 showed a RI time that was twice as long as the part 
of group I that only got CyA at the same dose. 
The representatives of group 2 in group 3 needed less CyA to clear the skin in a slightly 
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longer time than the part of group 2 that only got CyA. The small number of 
patients/episodes in this group only allows limited conclusions. 
Reasons to change doses or stop Cy A treatment in all groups were serious side-effects 
(creatinine rise, psychosis), drug interaction (ProlixanR), active intercurrent disease 
(asthma bronchiale) or the patient's wish. 
Hypertension was no direct reason to stop. An insufficient reaction to antihypertensive 
drugs was not seen. With the doses of CyA that were prescribed, not all arthropathy 
could be prevented casu quo cured. Several drugs were used for this aspect from different 
pharmacological groups. On these drugs no exceptional signs of nephrotoxicity were seen, 
with the exception of ProlixanR (azapropazon, an NSAID). This parmacon was the 
"routine"-prescription of the consultant rheumatologist during the trial period. 
Side-effects 
During these long-term treatment programmes the well-known side effects were seen but 
also other complications were noticed, mostly with small frequencies (Table V). Any 
effect returning in another episode in a patient was counted as one. 
Hypertension was seen in 47% of the patients (n=l9). For 6 patients adequate treatment 
was started. In group 2 the blood pressure normalized and the antihypertensive drug could 
be stopped after the weaning phase. 
A rise of creatinine was the second major side effect (42%). From these 8 patients 4 
received ProlixanR. 
The exact reason for weight increase is unclear. Nephrotoxicity may be a cause of this 
effect. 
Skin infections were not per se attributable to CyA treatment. Fatty ointments, being the 
basic skin care during this trial, might have facilitated bacterial phenomena. 
Gynecomastia is an intriguing reaction as CyA is supposed to have an influence on the 
balance of peripheral androgen-estrogen ratio in male patients [7]. Careful screening with 
X-ray and biopsies did not reveal other pathology of breast tissue in these cases. The 
side effects in the 3 groups did not have the same frequency. Group 3 showed far fewer 
undesirable effects. In group 1, gastrointestinal problems and weight increase were four 
times more frequent than in group 2. The incidence of hypertension in group 2 was twice 
that in group 1. 
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Discussion 
The doses needed to induce a remission in group 1 and group 2 ranged between 2.9 and 
8.4 mg/kg/d (mean 5.4 mg/kg/d). The overall clinical effect of the treatment procedure in 
group 1 and group 2 seem to be the same: a beneficial effect on the skin in maintenance 
periods of 24.3 vs. 23.4 weeks (Table IV). The cumulative amount of CyA needed to 
reach this results, however, is less in group 2. Even more important is the fact that the 
negative effects (renal function deterioration and hypertension) can normalize in the CyA-
free period. 
Although there is a known interaction of CyA with many drugs [1,2], IHN was judged to 
be necessary to prevent reactivation of tuberculosis. This event did not happen in our 
patients. 
Of the NSAID's that were taken during this trial, only ProlixanR (azapropazon) had a 
demonstrable impact on the renal function. A synergistic effect on the other hand, might 
be due to fish oil in patient 13, as we suggested elsewhere [2]. The 2 patients with 
diabetes mellitus had a serious hypertension (up to 200/110 mmHg). The nephropathy is 
not comparable as one of these cases received ProlixanR, but there might be a tendency to 
vasculopathic reactions. Although the epithelium of the airways in CARA patients is 
known to be colonized continuously with bacteria, and some consider this as a focus for 
psoriasis, we only treated asthmatic bronchitis with antibiotics and stopped CyA for a 
while. We got the impression that both (severe) diabetes and CARA were more difficult 
to maintain in a stable condition. 
Group 1 and group 2 with CyA as monotreatment, compared to group 3 with combination 
therapy, showed more side effects. The clinical results of group 3 could be compared to 
"group 2 results < 65%" (Table IVb). 
All the side-effects that were seen tended to normalize after lowering Cy A doses or 
disappeared after stopping the drug. In our opinion, the intermittent programme is 
superior. Main guidelines result from this study but an individual approach in monitoring 
CyA needs to be stressed. 
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Table 1. General data of patients in group 1 and 2, and duration of the CyA treatment 
Groupl Group2 
Patient Sex BW Age CyA Patient Sex BW Age CyA 
no. (kg)* (yrs) (wks) no. (kg) (yrs) (wks) 
2 M 63 63 100 1 M 60 30 25 
7 M 70 43 46 3 F 84 45 90 
13 M 75 66 130 4 M 83 54 141 
14 M 70 58 25 5 F 85 51 74 
15 F 50 43 51 6 M 66 66 30 
17 M 65 25 30 9 F 77 68 15 
\D 18 F 44 50 52 10 M 60 43 65 
en 19 M 90 63 44 11 M 75 64 66 
20 M 110 60 54 12 M 74 27 40 
16 F 69 39 24 
N=9 M/F=7/2 71° 52° 59° n=lO M!F=6/4 73° 49° 57" 
* initial body weight (BW) 
mean values 
group 1 + group 2: 
meanBW: 72kg 
ineanage: 50yrs 
M/F 13/6or68% and32% 
mean period of Cy A treatment: 58 wks 
Table 2. Remission induction and maintenance in group 1, continuous therapy over 1-4 exacerbations 
Patient IPtl Rlt2l dose3l Mt4l dose RI2 dose M2 dose RI3 dose M3 dose RI4 dose 
no. 
2 34 5 6.2 5 4.4 4 4.8 50 3.3 16 3.8 
p=lO p=10 p=lO p=lO 
7 50 17 6.6Pl 7.5 5.4 15 6T 
50% 7l 
13 27 8 5.6 28 2.5 3 4 46 2.1 9 2.9 12 2.7 3 4T 
14 58 5.5 5.6 19.5 4.9 
15 48 4.5 5.2 13 4.4 2 6.8 - - 2 6.2 7 4.2 
59% 
\0 17 32 4.5 6.2 12.5 3.1 3 5.7 
--.1 44% 
18 35 7.5 8.4 44.5 7.7 
19 25 2.5 5.2 4 3 2.5 3.3 33.5 2.8 
20 22 6.5 4.5 47.5 3.1 
Legends to Tables 2 and 3 
1) IP = initial PASI; mean value in group 1 = 37; group 2 = 36. 
2) RI =remission induction (wks) till PASI = 5, unless stated PASI (p) = 10. 
3) dose in mg/kg body weight/day. 
4) M = maintenance period, W = weaning phase, N = phase without CyA. 
5) T = TigasonR added (see text). 
6) 0 =weaning not to zero. 
7) 50% means percentual reduction till lowest P ASI. 
Table 3. Remission induction and maintenance in group 2, intermittent therapy, over 1-4 exacerbations 
Patient !PI) RJI2) dose3l Ml<l dose Rl2 dose M2 dose RI3 dose M3 dose RI4 dose M• dose 
no. 
28 3.5 6.7 w 9.5 4.2T'l 6 3.7T 
N 6.5 
3 20 4 6.0 w 3.5 5.5 6 3.7 - - 8 4.5 w 350 3.1 
N 7 42% 7) 
4 50 4 5.7 W31 4.2 10 5.7 - - 20 2.5T 
N 8 64% 57% 
\0 5 28 6 7.4 w 2706> 5.8 3 5.6 Tonly - - 8 2.5T w 330 0.8 OJ 
6 30 3.5 5.8 w 12.5 4.5 10 5.0 - - 8.5 6.1 
N 42.5 64% 
9 42 6 4.7 w 6 2.3 3 7.1 
N 16 
10 43 5 6.0 w 7 3.8 4 6.7 
N 10 50% 
11 51 5.5 5.2 w 6.5 2.5 8 4.8 w 30 3.6 7 4.0 6 5.3 
N 9 41% 
12 30 3.5 5.4 w 16.5 2.8 2.5 4.1 W10.50 4.3 
N 22 
16 35 4.5 4.9 w 0 0 3.5 4.4 w 3.5 2.8T 6 3.6 
N 17.5 N 7.5 
Table 4 
a. Comparance of remission induction (RI)-time and maintenance periods (weeks) in group 1 and 
doses (mg/kg/d), mean values 
Treatment P ASI reduction RI-time dose episodes Maint. time dose episodes 
> 65% 5.9 5.2 13 24.3 3.7 13 
CyA 
< 65% 4.5 5.8 3 
CyA > 65% 10 5.3 2 7.5 5.4 
& 
TigasonR < 65% 15 6 
b. Comparance of remission induction (RI)-time and maintenance periods (weeks) in group 2 and doses 
(mg/kg/d), mean values 
Treatment P ASI reduction RI-time 
> 65% 5 
CyA 
< 65% 9 
CyA > 65% 7 
& 
TigasonR < 65% 20 
* weaning not to zero 
dose episodes 
5.5 19 
4.7 5 
3.1 2 
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Maint. time 
weaning 6.9 
noCyA 16.5 
weaning* 33 
dose episodes 
3.2 8 
0.8 
Table 5. Side-effects in groups 1 and 2 (n=l9), group 3 (n=4) 
Group 
N (%) 1 2 3 
Serum creatinine> 130 J-lmol/1 8 (42)* 4 4 2 
Alkaline phosphatase> 75 U/1 4 (21) 2 2 1 
Platelets > 320 x 109/l 2 (11) 2 
Hypertension, diastolic pressure> 95 mmHg 9 (49) 3 6 1 
Weightincrease> 5kg 5 (26) 4 1 
Gastrointestinal complaints 5 (26) 4 1 
Hypertrichosis 3 (16) 2 1 
Gynaecomastia (2 males, 1 female) 3 (16) 1 2 
Verrucae vulgaris 2 (11) 2 
Folliculitis, furunculosis, intertrigo 2 (11) 2 1 
Paraesthesia 2 (11) 1 1 
Psychosis 1 ( 5) 1 
Orchitis 1 ( 5) 1 
Conjunctivitis 1 ( 5) 1 
* ProlixanR-related creatinine rise in 4 of these patients. 
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Summary 
The immunosuppressive properties of cyclosporin A (CyA) after systemic (oral) 
administration are now well documented in several dermatological disorders, especially in 
psoriasis. However, long-term oral use, even at low doses, is hampered by renal side-
effects. 
From a theoretical point of view in skin diseases there is an opportunity to bypass the oral 
route and administer CyA directly to the affected areas. The data of the experimental 
studies to date in psoriasis, alopecia, contact and atopic dermatitis as well as oral lichen 
planus and keloid scars are summarized and own experiences have also been presented. 
Theoretical considerations on the pharmacokinetics of CyA for topical application are also 
discussed. 
Introduction 
Cyclosporin A (CyA) has been used for the past ten years to treat a range of skin diseases 
with an acknowledged immunological background. The oral formulation of CyA (drink 
solution or soft gelatine capsules both containing 100 mg cyclosporin A per ml) used in 
short- and long-term treatment has side-effects that are now best evaluated in psoriasis. 
Among these, adverse effects on the kidney and hypertension are the most frequent. Other 
objective and subjective adverse effects were also recently reported [1]. The exact 
mechanism of action of CyA is not yet fully known but there is strong evidence that 
immunosuppression is induced via an antiproliferate effect on CD4+ helper T-lymphocyte 
subsets. A simultaneous inhibition of keratinocyte proliferation was also suggested [2]. 
Recent data also strongly indicate that CyA inhibits delayed type hypersensitivity. This 
may be partly due to impaired function of antigen presenting Langerhans cells [3]. Other 
targets for the biological activity of CyA may be inflammatory cells like neutrophils and 
the vascular endothelial cells. Whether such effects in human skin in vivo can be induced 
by circulating CyA or can also be induced by the drug administered topically (with or 
without a circulating fraction) is not yet clear [4]. Another route than the oral 
administration has many advantages if topical formulations of Cy A are therapeutically 
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effective, without showing the side-effects. 
Although a definite proof of local action of CyA cannot be given as yet, intra-epithelial 
accumulation and effects may be postulated from several studies. It is known from post-
mortem studies in transplant patients that CyA in fact has an affinity for skin tissue [5]. 
Investigation of suction blister fluid from patients with psoriasis who were treated with a 
mean oral dose of CyA of 3.9 mg/kg/d and who were in a steady state showed a blister 
fluid concentration (BFC) of between 20-113 ng/ml while the whole blood through levels 
ranged from 236-935 ng/ml. The BFC was approximately 1/lOth of the blood levels [6]. 
Intralesional injections with CyA result only in trace blood levels but produced a 
significant resolution in psoriatic plaques [7]. 
In this chapter, a summary of clinical trials with topical CyA in plaque psoriasis, 
psoriasis of the nails, alopecia, allergic contact dermatitis, oral lichen planus and keloid 
scars together with our own observations in these diseases is presented. 
Clinical experiences 
Psoriasis 
Topical CyA showed an inhibitory effect on psoriasis-like inflammation in mice. Fisher et 
al [8] studied this phenomenon in the tumor-promoting phorbol ester (TPA)-induced 
inflammatory response in mouse skin. There was a decrease in cell infiltrate, epidermal 
thickness, ornithine decarboxylase (ODC) activity, ODC-mRNA accumulation and 
prostaglandin ~ content. Protein kinase C, however, appeared not to be inhibited. 
The clinical studies with topical CyA treatment in chronic, plaque-type psoriasis were 
performed with 2, 5 and 10% CyA in a range of vehicles, containing several of the 
additives shown in the Table, some under polyethylene occlusion [11-17]. At our centre 9 
patients with psoriasis were enrolled in a double-blind, randomised study to compare a gel 
containing 10% CyA, 43% olive oil, 10% ethanol, 30% peglicol 5 oleate (Labrafil) and 
7% colloidal silicium oxide (Aerosil) with an identical placebo gel without CyA. On 2 
symmetric psoriatic plaques 0.3 ml of either gel was applied twice daily for 4 weeks. As 
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a result a total amount of 2352 mg CyA was applied to one lesion. No significant clinical 
difference was noticed between the CyA treated and the placebo treated lesions [17]. 
Also in other reported studies no therapeutic effect on the psoriatic plaques was observed 
using objective and subjective criteria, though some noticed a decrease in the number of 
neutrophils [14,16]. Blood samples taken to determine blood concentrations during the 
treatment showed inconsistent levels in a range that appeared to be too low to be 
therapeutically effective. In these trials no local or systemic side-effects were noticed. The 
barrier of the thick hyperkeratotic epidermal layers in psoriatic skin may be one of the 
causes for the lack of effectiveness. 
In nail psoriasis, Tosti et al. [18] mentioned a fair response of topical CyA in 4 months. 
These observations have, however, not yet been confirmed. 
lntralesional (injected or infused) CyA seems to be more effective [7,19-23]. The 
psoriatic skin tended to normalize in 5 days and in 4 weeks a significant resolution of 
lesions was observed in all cases. After 4 weeks a normal orthokeratotic pattern returned 
and epidermal and dermal accumulation of immunocompetent cells was decreased [20,23]. 
The blood levels were below sensitivity levels of HPLC and polyclonal RIA. Pain at the 
injection site and a cellulitis-like reaction were the major side-effects [20]. 
Alopecia areata and alopecia androgenetica 
More or less severe hypertrichosis, both in male and female patients [colour plate 5 and 
6], is reported as a side-effect of oral CyA in clinical trials by several authors (see 
Chapter 1). An effect on the androgen production seems not of a major importance as 
women show no virilization and some of the skin sites such as the earlobes and the nose 
that are involved are non-androgen dependent. 
CyA induces the appearance of large follicles that produce thick hair stems besides vellus 
hairs tum into terminal hairs. After withdrawal of CyA the new hairs fell out quickly. 
Both male pattern baldness or androgenetic alopecia which is a testosterone induced 
disease with an involution of anagen to catagen hair or even dysplastic hair roots and 
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alopecia areata which is a condition that shows an involution of the hair follicle and hair 
loss and is marked by a perifollicular infiltrate of T -lymphocytes have been treated locally 
with CyA [2,25-32]. 
In a two-months experiment in a 45 year old man with a longstanding androgenetic 
alopecia totalis who was treated with 5% CyA-cream (as oral suspension in cremor lanette 
FNA), double-blind, vehicle controlled, no substantial regrowth of hair was observed 
(own unpublished observations, 1985). 
Gilhar et al. [30] evaluated topical CyA in a 4 month, double-blind study in male pattern 
alopecia. Significant regrowth was seen in 2 out of 8 patients but only in one hairgrowth 
was cosmetically satisfactory. A few sera in this trial showed trace amounts of CyA. 
Parodi and Rebora used only 0.25% CyA in an alcohol/propylene glycol-containing 
medium to treat a patient with alopecia areata. This treatment resulted in complete hair 
regrowth after 16 months [27]. 
Though the results of the oral treatment with CyA seem promising in alopecia variants [1] 
the local application has not yet resulted in a reproducible, satisfactory response. 
Contact dennatitis 
In contact allergy a T-cell-mediated response is provoked by an allergen resulting in 
clinical dermatitis. The initial investigations with CyA to evaluate the cell-mediated 
immune response was quantified as immune delayed-type hypersensitivity (DTH) reaction 
by measuring the suppression of the oxazolone induced skin reaction in mice [33]. In 
animals [34-39] and in man [32,40,41] a decrease in DTH in the skin was noticed after 
topical application of Cy A containing formulations. The mechanism of action may be a 
sufficient inhibition of the function of Langerhans cells present in the epidermis to 
suppress activation ofT-lymphocytes. 
Aldridge et al. [34] found a beneficial effect of 1-2% Cy A in ethanol/ olive oil 1 : 2 on 
dinitrofluorobenzene (DNFB)-induced contact allergy in guinea-pigs. CyA blood levels 
were lower than 50 ng/ml and they recorded no systemic side-effects. 
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Duncan et al [9] found that a DTH reaction to DNFB in guinea-pigs could be suppressed 
by a topical CyA formulation containing Azone and propylene glycol. Both the erythema 
response and the T-cell infiltrates were reduced on the test-sites on a 0.25, 0.5 and 5% 
CyA concentration compared to the vehicle treated sites. 
Our own unpublished observations in two patients are as follows. 
An adult male patient presented with a dermatitis due to wool alcohol. The allergen (wool 
alcohol) in combination with 5% Cy A and the allergen without Cy A were tested 
epicutaneously according to standardized test procedures. After 48 hours, the test site 
with CyA showed a reduction in response of about 50% as compared with the site without 
CyA. 
A 45-year-old woman with longstanding psoriasis who suffered from hand-involvement 
was treated with systemic CyA. Her skin became quiescent. To exclude triggering contact 
factors (Koebner phenomenon) patch-tests were performed, but all tests were negative 
under CyA treatment. However, once the dose of CyA was decreased and then 
withdrawn, the eruption on the hands became worse upon contact with rubber household 
gloves. Skin-tests were performed again (3 months after stopping CyA) and strong 
positive reactions to rubber constituents and to her own gloves were observed. The DTH 
reaction in this case was hidden in the psoriasiform Koebner reaction due to the inhibitory 
effect of oral CyA. 
Atopic dermatitis 
Atopic dermatitis presents with an array of skin signs such as pruritis, redness, vesicles, 
oozing, urticarial swelling, dryness, scaling and lichenification often with a seasonal 
periodicity. 
These can be explained mainly on the basis of both 1gB-mediated humoral and cell-
mediated immune mechanisms. In many patients immediate-type allergies can be detected 
for aero-allergens (pollens, house dust mite, human and animal dander). Systemic 
treatment with CyA was shown to have a beneficial effect in atopic dermatitis, especially 
the pruritis responded well [42], suggesting that the production and/or liberation of 
certain cytokines responsible for the pruritis were affected in rather short time. We 
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observed no effect on the serum IgE levels and this was confirmed by others [43]. The 
prick-test responses to aero-allergens were also unaffected by CyA [43]. This may 
emphasize the role of T -cell mechanisms in atopic disease. 
De Prost et al [44] compared a gel containing 10% CyA with placebo in atopic dermatitis 
during 2 weeks. The improvement in pruritis, erythema, oozing, crusts, xerosis and 
lichenification was significantly superior at the sites treated with CyA than at the sites 
treated with placebo. No complete cures were observed. Blood CyA levels were always 
below the limit of detection. No systemic reactions were observed but irritation of the 
excipient (its alcoholic component?) was a major problem. 
Oral lichen planus 
The painful, debilitating erosive lichen of the oral cavity is histologically characterized by 
a heavy bandlike lymphocytic infiltrate consisting of the T -helper/inducer subtype at the 
dermal/epidermal junction. The epidermis shows increased numbers of T6-HLA-DR+ 
Langerhans cells but rarely dendritic cells. The surface of the keratinocytes also express 
HLA-DR antigen and intercellular adhesion molecule-1 (ICAM-1). Oral CyA treatment of 
cutaneous lichen planus reduced the lymphocytic infiltrate by 20% after 8 weeks and 
expression of ICAM-1 was no longer observed [50]. 
Several clinical studies with CyA in some form of a mouth wash [45-54] with daily 
amounts ranging from 1 [45] to 5 [48] ml CyA solution containing 100 mg/ml showed a 
very good response after 2 months. No systemic or local side-effects were noticed even 
though gum hyperplasia was reported after systemic therapy [colour plate 4]. The oily 
solution only left a waxy debris in many patients. 
Analysis of the CyA content in the buccal mucosa revealed quantities that equalled those 
after systemic use [50]. The lack of cornified layers resulting in a better penetration of 
CyA could explain the therapeutic effect in this disease of the oral mucosa. Incidental 
reports on the swish and spit method in other mucosal diseases like bullous pemphigoid, 
cicatricial pemphigoid, pemphigus vulgaris and aphtous stomatitis do not allow firm 
conclusions yet [51,52]. 
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Keloid scars 
Hypertrophic scars can appear in the presternal area, over the deltoid region and on the 
earlobes. Apart from an increased collagen deposition by fibroblasts a perivascular T-cell 
infiltrate is thought to be relevant. The topical application of Cy A resulted in a decreased 
T -cell infiltrate but did not alter the clinical picture [53]. 
Conclusions 
Oral CyA has proved to be effective in a range of dermatological diseases with a 
suspected cell-mediated immunological involvement. 
Topical application to the human skin, however, did not show the expected response in 
many studies. Newer approaches with intralesional administration and the swish and spit 
method for oral mucosal diseases seem more beneficial and indeed prove the local action 
of the drug. 
The main explanations for the lack of effect of topical therapy can be summarized as 
follows. From a logistic point of view the principal barrier of the skin is the stratum 
corneum, this is especially true in psoriasis. CyA has a chemical structure with a 
relatively high molecular weight of 1.2 kD without an ionic polarization and it has a 
cyclic configuration. This combination of factors is a disadvantage for penetration 
although its lipophilic nature is an advantage. A poor penetration results in minimal 
absorption into the circulation. However a circulating fraction of CyA might not be 
necessary for the local action. A low local concentration that is insufficient to produce 
any therapeutic effect may also ensue from a quick absorption into the circulation 
(washout phenomenon). Absorbed and circulating CyA is metabolized in the liver and 
active metabolites on one hand may be responsible for the effects in the skin. Whether a 
proper metabolization in the skin per se takes place is still under investigation [55]. A 
high local turnover to inactive metabolites on the other hand may render it ineffective. 
The effectiveness of CyA metabolites is under investigation to obtain a precise image of 
structure-activity relationships but much more remains to be done. When CyA binds to 
elements in the skin for instance cell membranes of erythrocytes or keratinocytes and 
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lipoproteins it may not reach target cells like Langerhans cells or T -lymphocytes. 
Among all these penetration through the stratum corneum seems a manageable factor. The 
solubility and the concentration of CyA in the formulation is important and so is its 
ability to redissolve for the duration of application. By increasing the hydration state and 
lipid fluidity of the stratum corneum the penetration may be increased. A list of 
substances with such qualities (enhancers) is shown in the Table. The study by Duncan et 
al [8] requires special attention. They demonstrated that the addition of penetration 
enhancers resulted in therapeutic effects of Cy A doses which were otherwise ineffective. 
Further pharmacokinetic studies in vitro with skin slice models, skin homogenates and 
skin perfusion models, the in vivo application of radiolabelled substances in animal and 
man [56] are necessary to explore newer topical formulations with increased penetration. 
Such formulations would allow the effective therapeutic treatment of skin diseases without 
the adverse effects of the drug. 
Table 
Penetration enhancers [8,9] 
Salicylic acid 
Urea 
DMSO (dimethylsulphoxide) 
Liposomes 
Azone (1-dodecylazacycloheptan-2-one) 
Tween 80 (sorbitan mono-oleate) 
Labrafll (peglicol 5 oleate) 
Propylene glycol 
Ethanol 
Imvitor (monoglyceride of caprilic acid) 
Pyrrolidones 
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Summary 
The efficacy of cyclosporin A (CyA) in severe psoriasis is well established. However, 
there is genuine concern regarding the safety of long-term treatment with CyA. To date 
proper assessment of the extent of CyA-induced renal damage has been hampered by the 
crudeness of serum creatinine as a parameter to estimate glomerular filtration rate (GFR). 
The objectives of this study are a prospective evaluation of renal function at two doses of 
Cy A with special emphasis on 1 - lowest effective dose, 2 - reliability of serial serum 
creatinine measurements to monitor changes in GFR and 3 - complete reversibility of renal 
dysfunction after stopping CyA. 
This study is designed as a prospective, open, randomized multi-center trial in parallel 
groups in which the efficacy of 2.5 or 5.0 mg of CyA per kg/dis compared. Induction 
period: 3 months. Maintenance and tapering-off period: maximum 16 months. Post-
treatment period: 3 months. After four weeks, the 2.5 mg dose may be adjusted to 
improve efficacy, the 5.0 mg dose may be reduced for safety reasons. 
Six departments of dermatology in the Netherlands were involved in this study. 
Seventy-four patients with severe plaque-type psoriasis were included. The results can be 
summarized as follows: 
The speed, magnitude and duration of improvement appeared to be dose-dependent, the 
5. 0 mg dose being the more effective. However, when the resolution of the lesions of the 
skin is relatively unimportant, 2.5 mg/kg/d was a good starting dose since minimal side-
effects were observed. In the patients treated with 5.0 mg/kg/d, 22% required dose 
adjustments for safety reasons (increase in serum creatinine ::::: 30% of the base line). At 
the end of the induction period the GFR in 44 patients decreased by 15% on the average 
(p < 0.01). In the range of GFR observed (mean 115 ml/min, range 51 to 216) serum 
creatinine appeared to be a poor predictor of changes in GFR. The effective renal plasma 
flow (ERPF) decreased by 16% on the average (n=27, p < 0.01). Prolonged treatment 
with CyA during the maintenance phase did not lead to a further reduction in the GFR and 
ERPF. After stopping Cy A, serum creatinine returned to baseline values. In contrast, GFR 
and ERPF remained significantly below pretreatment values, 6 and 8 percent respectively. 
In conclusion can be stated that low-dose CyA therapy was effective in the majority of 
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patients. Since serum creatinine was relatively insensitive in predicting mild to moderate 
reductions in renal function, long-term follow-up with precise measurements of GFR and 
ERPF is mandatory to ascertain the risk of chronic irreversible renal damage. 
Introduction 
Psoriasis is a multi-factorial skin disease characterized by abnormal keratinocyte 
proliferation and elevated levels of inflammation causing mediators [1]. A genetically 
determined disturbance of epidermal immune mechanism probably underlies the disease 
process [2]. Since the original report of Mueller and Hermann [3], the efficacy of 
cyclosporin A (CyA) in the treatment of severe psoriasis has been well documented 
[4-9]. The dose of CyA in these studies, however, varied markedly (1-14 mg/kg/d) and 
its use had been associated with the occurrence of renal dysfunction and the development 
of hypertension. 
The cellular or molecular mechanisms behind these adverse effects are as yet incompletely 
understood [10-12]. From the experiences of CyA use in organ transplantation, it appeared 
that CyA induces a new form of drug toxicity in which functional vasoconstrictory effects 
consisting of dose-dependent reductions in glomerular filtration rate (GFR) and renal 
plasma flow (RPF) were accompanied by morphological structural damage in the kidneys 
[13]. Arteriolopathy (endothelial and smooth muscle cell damage), 'striped' form 
interstitial fibrosis and focal tubular atrophy have been observed in kidney biopsies 
obtained from patients treated with high, vasoconstrictory, doses of Cy A (8-17. 5 mg/kg/ d) 
[13-15]. 
At present it is unknown whether the dose-dependent, reversible, functional effects of the 
drug, i.e. renal vasoconstriction, leads to structural renal damage, although there is 
certainly evidence suggestive of this. It has been shown that the risk of developing 
irreversible structural alterations in the kidney is closely related to the severity of CyA-
induced renal dysfunctions [16]. 
The genuine concern about CyA-induced nephrotoxicity has resulted in several studies 
designed to determine the lowest effective dose range [8,17,18] and the use of CyA has 
been beset by "safety rules" [19-21]. The dose of CyA in autoimmune disorders, 
particularly in psoriasis, should not exceed 5 mg/kg/d and as soon as unacceptable renal 
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vasoconstriction occurs i.e. increases in serum creatinine of 30 to 50% over baseline 
values, the dose of CyA should be reduced. A pooled analysis of data obtained in a large 
series of psoriatic patients who were treated along these guidelines suggested that strict 
adherence to these guidelines enabled a reasonably safe use of CyA for a prolonged period 
[22]. However, proper assessment of the extent of CyA induced renal damage in these 
patients was hampered by the relative crudeness of serum creatinine as an indicator of 
glomerular filtration rate (GFR) [23]. Serum creatinine, although widely used clinically 
to monitor renal function is not an ideal filtration parameter. It is excreted both by 
glomerular filtration and tubular secretion. Serum creatinine and creatinine clearance thus 
would be expected to over-estimate GFR at all levels of renal function. Furthermore, Cy A 
even at low-dose is known to exert important functional tubular effects [24] and the 
possibility that CyA somehow alters the tubular manipulation of creatinine has received 
insufficient attention. Therefore, the poor correlation between changes in serum creatinine 
and decline in GFR observed in transplantion and non-transplantion patients treated with 
CyA is not surprising [25-28]. However, the question whether CyA induced renal 
dysfunction is completely reversible after CyA is withdrawn, is more important since 
serum creatinine and creatinine clearance are poor predictors of mild to moderate 
reduction in GFR. The present Dutch Psoriasis Multicenter Study was undertaken to 
determine the efficacy and the safety of two low-dose regimens of CyA in 74 patients with 
severe psoriasis and to assess the reliability of serial serum creatinine measurements to 
monitor changes in renal function (as reflected by measurements of true GFR in these 
patients) and to assess the reversibility of renal dysfunction after prolonged CyA treatment 
(maximum 16 months). 
Patients and Methods 
Patients 
Seventy-four adult patients were enrolled (average age 38 years range 20-75, 45 males and 
29 females). They participated in a multi-center study in which two CyA dose schedules 
(2.5 versus 5.0 mg/kg/d) were compared for induction and maintenance of remission. Six 
departments of dermatology in the Netherlands co-operated in this trial. The participating 
centers and the number of patients they included are listed in Table 1. All patients had 
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severe psoriasis as defmed by a Psoriasis Area and Severity Index (PAS I) score ~ 18 [29] 
[Addendum 1]. The mean PASI score at inclusion was 22 (range 18- 55) and the duration 
of the disease ranged from 1 to 46 years (mean 12 years). Exclusion criteria were drug-
induced psoriasis eg by lithium or beta-blockers, serum creatinine above 100 /kmol/1, 
bilirubin or liver enzymes above twice the upper limit of the normal range, hyperkalemia, 
hyperuricemia, hypertension i.e. diastolic blood pressure over 95 mmHg, malignancy or 
history of malignancy, acute uncontrolled infections, pregnancy, concomitant therapy with 
nephrotoxic compounds or drugs which are known to interfere with the pharmacokinetics 
ofCyA. 
Patients with a history of epilepsy, drug or alcohol abuse or a malabsorption syndrome 
were also excluded. Previous oral therapy in these patients consisted of methotrexate, 
retinoids (Neo-Tigason') or photo-chemotherapy. Results of these therapies are summarized 
in Table 2. Methotrexate, retinoids or PUV A/UVB were stopped at least 2 weeks and 
specific local therapy at least 1 week before entry into the study. The protocol was 
approved by the Ethical Commitee of each participating center and written informed 
consent was obtained from each patient. 
Study design 
The study consisted of 3 parts (Figure 1). In Part 1, an open randomized parallel-group 
study, the efficacy of two dose regimes of CyA (group A, 2.5 mg/kg/d versus group B, 
5.0 mg/kg/d) were compared (month 0-3). Patients were randomly allocated to receive one 
of the dose regimes. Cyclosporin A was taken at mealtimes as soft gelatin capsules of 25 
mg and 100 mg in two separate doses and was provided by Sandoz BV, Uden, the 
Netherlands. Sandoz, Basle, provided the randomization schedule which was stratified for 
the participating centers. Thirty-two patients were randomized to receive 2.5 mg/kg/d and 
42 patients to receive 5.0 mg/kg/d. At the end of month 1 or month 2, a PASI reduction 
of 10% or more meant continuing the same dose. In case of inefficacy (Failure at month 
1 or 2, F1 or F2, see Figure 1), i.e. a PASI reduction ~ 10%, patients from group A 
could move to group B. For those already in group B, failure meant discontinuation of 
Cy A. At the end of part 1 (month 3) a PASI reduction > 75% or a P ASI < 8 was scored 
as "success". These patients entered part 2 of the study. Patients who did not fulfill these 
criteria progressed to part 3. A reduction of the PASI score < 10% for those in group A 
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(failure at month 3, F3) implied entry into group B. 
In Part 2, an open study, we attempted to maintain (month 4-16) the remission induced 
previously. Patients from group A continued to take 2.5 mg/kg/d CyA until the end of 
month 12. Patients from group B followed a tapering to 2.5 mg/kg/d CyA at the end of 
month 7. They then stayed on this dose until the end of month 12. Patients from both 
groups were tapered off CyA during month 13-16. In case of relapse (month 7-12), 
defmed as an increase of the PASI > 50% above baseline, the dose of CyA was 
temporarily increased to 5.0 mg/kg/d and then tapered down to zero again during month 
13-16. After a second relapse patients entered part 3. At any time during parts 1 and 2 of 
the study, the Cy A dose was reduced by 25% in case of adverse events such as a rise in 
serum creatinine > 30% over baseline or above 130 ,umol/1, a rise in serum potassium 
above 5.5 mmol/1 or definite liver dysfunctions. If the abnormality had not improved by 
the next visit, a further 25 % dose reduction was carried out. If this failed to achieve the 
desired effect, CyA had to be withdrawn and the patient entered into Part 3. 
All patients who had received CyA for some time (3-16 months) had to participate in Part 
3 of the study, a post-treatment period lasting 3 months, in which the reversibility of any 
CyA-induced abnormality was assessed. 
Efficacy 
A global rating that reflected the percentage and severity of body quadrants affected by 
psoriasis, ranging from 0 to 72, the psoriasis area and severity index (P ASI) [29] was 
evaluated at each visit. Each patient was seen by the same physician at all visits, with a 
few exceptions. 
Measurements of renal function 
Serum creatinine and creatinine clearance 
Evaluation of CyA-associated renal dysfunction was based on serum creatinine levels and 
a modified Cockcroft formula [30] predicting creatinine clearance (Ccr) from serum 
creatinine, body weight, age and sex. 
Mal C 28 - 0.2 * age Cyr) *b d . ht(k )*6 15 es : cr = serum creatinine (.umol/1) 0 ywelg g . 
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Results are expressed as absolute values and as percentage increase over baseline. In the 
first 3 months induction period, serum creatinine was measured every week for the first 
month and then at the end of weeks 6, 8 and 12. In addition to values taken at a fixed 
time-point, the maximum serum creatinine concentration (or increase) and matching 
predicted creatinine clearance with Cy A treatment were selected as a key parameter. This 
was because renal dysfunction was often transient as the dose was reduced each time it 
occurred. The maximum value during the treatment period for each patient was thus a true 
reflection of renal dysfunction. During the maintenance and 3 months post-treatment 
period, serum creatinine was measured every 4-6 weeks. To establish reversibility of CyA-
associated changes in serum creatinine, the highest levels during the induction phase were 
compared with the last values obtained during the post-treatment period. 
Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) 
GFR and ERPF were measured at baseline, months 3 and 12 and finally 1-3 months after 
cessation of CyA. At the 4 centers which participated in these measurements, two different 
techniques were used. Two centers used single-shot techniques without urine collection 
[31]. Our center (University Hospital Rotterdam Dijkzigt) and the center at the Free 
University Hospital Amsterdam used the more laborious constant-infusion method with 
urine collection [32,33]. With the last method glomerular filtration rate (GFR) and 
effective renal plasma flow (ERPF) were measured simultaneously as the clearance of 1251-
iothalamate and 1311 -orthoiodohippurate (Amersham, UK) respectively. After priming doses 
of 0.1 ~tCi/kg body weight of thalamate and 0.3 ~tCi/kg body weight of hippuran, the 
radiolabels were infused at constant rates of 0.2 and 0.05 ~tCi/min, respectively. After an 
equilibrum period of 120 minutes, two clearance periods were obtained. These periods 
varied in length (20 to 40 min) depending on the subject's ability to void. Urine was 
collected without the use of a bladder catheter in order to avoid the risk of infection. 
Water and soft drinks were given freely in order to induce urine production in the order 
of 300 to 500 ml/hour. Blood samples were taken at the start and end of each clearance 
period from a cannula placed in the brachial vein of the non-infused arm. Radioactive 
counts of 1251-iothalamate and 1311-iodohippurate in the plasma and urine were measured 
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using a gamma scintillation counter. The standard formula, Cx= CUxV)/Px was used to 
calculate clearance values. Ux and Px denote urine and plasma concentration of the 
radiolabels, Cx stands for clearance and V is urine flow rate. The mean GFR and ERPF 
ware calculated from the two clearance periods. Coefficients of variations for GFR and 
ERPF were 8 and 11% respectively. 
At the other centers GFR was measured by the rate at which 51Cr-edetic acid e1Cr-EDTA) 
disappeared from the plasma. At 2, 3 and 4 hours after injection, blood samples were 
taken and GFR was calculated according to the mathematical model of Brochner-
Mortensen [31]. ERPF was estimated from a single injection of 1311-orthoiodohippurate. 
A blood sample was drawn at 44 min after injection. The ratio of injected-dose counts to 
plasma counts was used to calculate ERPF using the empirical equation derived by Tauxe 
et al [34]. Standard errors of GFR and ERPF determined by the single shot technique were 
reported by these centers to be 6 ml/min and 10 ml/min respectively. 
Blood pressure 
Blood pressure was measured with a mercury sphygmomanometer after a few minutes rest 
at each clinical visit. Elevated blood pressure was defined according to the World Health 
Organization (WHO) definition (systolic BP ~ 160 mmHg or diastolic BP ~ 95 mmHg). 
If a patient had persistent elevated blood pressure (at three consecutive visits) 
antihypertensive therapy was started as recommended in the protocol. More detailed 
measurements of blood pressure and heart rate (every 15 minutes for 3 hours) were 
performed at the centers in Rotterdam and Amsterdam during the renal function studies 
with automatic semicontinuous oscillometric blood pressure measurement devices 
(Accutorr, Dinamap). 
Routine serum chemistry and cyclosporin assay 
Blood CyA levels were measured using radioimmunoassay. A monoclonal antibody was 
used to characterize the parent drug [35]. Unless stated otherwise, all blood samples were 
collected in EDTA tubes before administration of CyA ("trough"). Haemoglobine, total 
white blood cell count, platelets, uric acid, potassium, magnesium, total bilirubin, liver 
enzymes and glucose were also determined, and at regular intervals urine was checked for 
protein and glucose. 
127 
Statistical analysis 
Results are presented as mean ± 1 s.e.m. on median and range. Differences within 
assigned treatment groups were evaluated by paired t-test and differences between groups 
by unpaired t-test. When exploratory data analysis showed significant deviations from the 
normal distribution or inequality of variances, non-parametric tests were used (Wilcoxon 
matched pairs rank sum test and Mann-Whitney rank sum test). Correlations among 
variables were determined by calculation of Spearman's rank correlation coefficient. All 
p-values are two-tailed. Data were analyzed with the Statistical Package for the Social 
Sciences (SPSS inc., Chicago, illinois, U.S.A.) 
Results 
Part 1 -Induction period, months 0-3 
Efficacy of cyclosporin treatment 
From the 74 patients enrolled and randomized, 64 patients completed the 12 weeks 
treatment with CyA (Table 3). At the 2.5 mg/kg/d dose regime (group A, n=32), there 
was a P ASI reduction of 30% after 4 weeks of treatment. This was rather low. It 
contrasted sharply with the 73% response in the 42 patients randomized in group B. The 
administration of the two initial doses of Cy A resulted in substantial overlap among the 
patients' average blood trough levels between the second and the fourth week. The 
correlations between relevant variables and dose and blood levels of CyA after four weeks 
of fixed dose therapy are shown in Table 4. At that time clinical improvement as reflected 
by the P ASI score did not correlate with the dose any better than with the trough blood 
level of Cy A. 
Twelve of the non-responders in group A continued with CyA at 5.0 mg/kg/d. Ten of 
them responded to the treatment. The PASI scores of the 20 patients who were finally 
treated with 2.5 mg/kg/d and the PASI scores of the 44 patients who were treated with 5.0 
mg/kg/d or less are shown in Figure 2. Response rate and effectiveness differed 
significantly in both groups. The correlation between the reduction of the P ASI score and 
the duration of the active disease, the initial level of the P ASI score and age of the patients 
was low. The following trend was observed: longstanding psoriasis was characterized by 
a higher initial P ASI score that responded better to Cy A in part 1 of the trial. During the 
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whole induction period trough levels of Cy A showed an enormous interindividual variation 
(Figure 3). Nevertheless, there was a significant correlation between the dose and the 
average blood level of parent CyA (r=.42, p=.OOOO, n=495 measure points). 
Side-effects and safety of cyclosporin treatment 
The side-effects observed during Cy A treatment are listed in Table 5. Only in two patients 
from group A, CyA had to be stopped, in one because of a rise in serum creatinine of 
more than 30% above baseline (78 to 113 /Lmol/1) and in the other because of 
hypertension. Dose reduction, however, because of renal dysfunction and/or hypertension 
was necessary in 10 out of the 42 patients randomized in group B. Figure 4 shows a time 
plot of the effects of Cy A on blood pressure and renal function in the 64 patients who 
completed the 12 weeks treatment period (20 patients had received 2.5 mg/kg/d, 44 
patients had received 5.0 mg/kg/d or the reduced dose). CyA induced a dose-dependent 
increase of serum creatinine and a decrease of calculated creatinine clearance. Changes 
in the clinical and the laboratory variables during the induction period (fixed-dose phase 
versus the adjusted-dose phase) are summarized in Table 6. Serum creatinine in the 
patients receiving 2.5 mg/kg/d did not change significantly. The maximum increase of 
creatinine, however, at some time during the 12 weeks period was 15 ±2% (baseline 
serum creatinine level 82±3 /Lmol/1, peak values 94±3 ILmolll). For the 44 patients 
treated with 5.0 mg/kg/d or less, serum creatinine rose from 80±2 to 87±3 /Lmol/1 with 
peak levels of 98±3 /Lmol/1 (+23±3%). 
From the 64 patients who completed the induction period, detailed measurements of the 
GFR were obtained in 44 patients (Figure 5). ERPF was determined in 27 patients. After 
twelve weeks of treatment, the GFR and ERPF decreased by a mean of 13 and 19% 
respectively, in the patients receiving 2.5 mg/kg/ d Cy A (group A, n = 16) and 15 and 14% 
in those receiving a mean dose of 4.8 mg (group B plus non-responders group A, n= 28) 
(Table 6). In the latter group the decrease in the GFR was accompanied by a significant 
rise in serum creatinine and calculated creatinine clearance. In contrast, the decrease in 
GFR in the patients of group A was not apparent from measurements of serum creatinine. 
As already mentioned, twelve patients initially randomized in group A were switched to 
group B because of clinical inefficacy. This should be taken into account when group 
differences are considered. For all patients of group A and B together (Figure 6), GFR 
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decreased from 121±64 ml/min at baseline to 99±4 mllmin at the end of the induction 
period (decrease of 14±2%, p<0.017). The decrease ofERPF was in the same order of 
magnitude, 12±3% (baseline, 504±35 ml!min; week 12 CyA, 428±22 ml/min, p<0.01). 
Filtration fraction did not change significantly. Regression analysis demonstrated that 
change in serum creatinine was a poor predictor of changes in the GFR. A weak 
correlation was observed between the change in serum creatinine and the change in GFR 
(r=0.32, p<0.05, n=44). The change in calculated creatinine clearance correlated 
slightly better with the change in GFR (r=0.38, p<0.05). 
Part 2- Maintenance and tapering period (4-16 months) 
The number of dropouts during this period was considerable. From the 64 patients that 
entered this part of the study, only 14 completed part 2 of the trial completely till month 
16. The actual numbers and the reasons for dropping out are shown in Tables 7 and 8. For 
most patients (23 out of 49) relapse of the disease and therefore unwillingness to go 
through with the rather long tapering phase was the main reason to leave the study 
prematurely. This is reflected by the actual moment of dropping out i.e. the step-wise 
decrease in the dose at the end of months 6, 12 and 15. Dropouts, dose reductions andre-
entries resulted in a rather heterogenous group in which the results of clinical and 
laboratory parameters could not be related to the original2.5 or 5.0 mg/kg/d doses. From 
the 44 patients who took part in the nephrological study during the induction period 
(months 0-3), detailed measurements of blood pressure and renal function after CyA 
treatment for at least 12 months was obtained in 21 patients. The main findings are 
summarized in Table 9. Prolonged CyA treatment did not lead to an additional reduction 
in GFR and ERPF. On the contrary, the gradual reduction of the dose to 2.5 mg/kg/d 
dictated by the protocol led to an improvement in renal functions and a decrease in blood 
pressure. Baseline values, however, were not reached. 
Part 3 - Post-treatment observation 
From the 64 patients who were treated with CyA for at least 3 months, reversal of CyA-
induced renal dysfunction was observed in 53 patients (at least one measurement of serum 
creatinine after stopping CyA). The percentage changes are shown in Figure 6. At 1-3 
months after stopping CyA, the creatinine level was 0±2% higher (not significant) than 
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baseline. For the 32 patients whose GFRs were measured after stopping CyA therapy, 
mean GFR was 113±5 ml/min during the post-treatment period compared with 121±6 
ml/min before CyA treatment (decrease 6±2 %, p<0.01). ERPF (measured in 26 
patients) also did not return to pre-treatment values. It remained 8±2 % (p < 0.01) below 
baseline. In contrast, serum creatinine and predicted creatinine clearance also in this subset 
of patients did not differ significantly from baseline values. 
Discussion 
The present Dutch Multi-Center Study confirms earlier reports (4,6,8,18) that low-dose 
cyclosporin A is an effective therapy for severe psoriasis. Our results suggest that an 
appropriate initial dose of Cy A lies between 2.5 and 5. 0 mg/kg/ d. When resolution of the 
lesions is relatively unimportant, 2.5 mg/kg/d may be a good starting dose as it has less 
side-effects. In addition, 83% of the treatment failures using 2.5 mg were successful after 
the dose was increased to 5.0 mg/kg/d. Hence, tachyphylaxis did not occur in patients who 
started with a low dose. Conversely, approximately 20% of the patients who were treated 
with 5.0 mg/kg/d required dose adjustments because of adverse effects. 
Improvement in psoriasis was maintained in the majority of patients taking a consistent 
dose of CyA. In the 5.0 mg/kg/d group, attempts to reduce the dose to 2.5 mg/kg/d 
resulted in a high relapse rate. Thus it seems very likely that the maintenance dose is very 
close to the minimum effective dose. Relapses did occur in nearly all our patients after 
stopping CyA. Continuous therapy, therefore is necessary for a long period of time. 
Psoriasis, however, is not a life-threatening disease and the long-term use of a potentially 
harmful drug such as CyA must be carefully evaluated and monitored. The main concern 
in the use of Cy A is the risk of irreversible renal damage. 
Therefore, in the present study, recommendations described in the introduction were 
strictly adherent in order to minimize the adverse effects of CyA. Dose adjustments 
because of a rise in serum creatinine of greater than 30% over baseline were carried out 
in 11 (14%) out of 74 patients. Adjusting the CyA dose on the basis of serum creatinine 
resulted in a stable creatinine level in our patients. The effect of CyA on the GFR was 
measured in 35 out of 44 patients and these results are compared with other reports in 
Table 10. With regard to long-term nephrotoxicity, the GFR and ERPF did not decrease 
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further in our 21 patients who were treated with CyA for one year. On the contrary, at 
an average dose of3.7 mg/kg/d the GFR was 8% below baseline (14% at 3 months) and 
the ERPF was 9% lower (15% at 3 months). None of our patients developed protracted 
renal dysfunction and no significant difference in mean creatinine concentration as 
compared to baseline was observed 3 months after stopping treatment. 
Does this mean that no harm was ·done to the kidney? We are not so sure! Glomerular 
filtration rate (n=33) and effective renal plasma flow (n=26) after cessation of CyA in 
patients who were treated for an average of 9 months (range 3-16) were significantly 
different from baseline values. GFR and ERPF in fact remained 6±2% and 8±2% 
respectively, below the values measured prior to therapy. In contrast, serum creatinine and 
calculated creatinine clearance had returned in this subgroup as well, to the pretreatment 
values. Therefore, the validity for assessing the reversibility of CyA-associated renal 
dysfunction based on serum creatinine measurements alone should be questioned. 
In our patients, the relation between the rise in serum creatinine and the fall in GFR was 
weak indicating that during treatment with Cy A, serum creatinine levels can be used only 
as a very rough guide for GFR. Our results confirm findings in renal and non-renal 
transplant patients who were treated with CyA. In these patients there was also a poor 
correlation between changes in serum creatinine and decline in GFR [25,37]. 
Besides the effects of Cy A on GFR, we were rather concerned by a lack of return of 
ERPF to baseline values after cessation of CyA. It could imply that renal vasospasm early 
in the course of CyA therapy in time results in some structural alteration of the renal 
vascular bed. In this regard, determination of renal blood flow is more discriminating than 
GFR, because the single nephron GFR of remnant glomeruli that remain perfused could 
be adaptively increased, thereby, compensating for the declining number of functional 
nephrons. Histopathological observations in heart transplant recipients [38] suggested that 
the cortical microvasculature had undergone progressive damage and alterations due to 
continuous treatment with CyA beyond 12 months. 
However, all reports on the occurrence of CyA nephropathy in transplant recipients and 
in autoimmune diseases were based on initial CyA doses of higher than 7 mg/kg/d. In 
contrast, in patients with lupus erythematosus or rheumatoid arthritis on 5 mg/kg/d [21] 
and psoriasis patients on 3,9 mg/kg/d [16] treated for 14-42 and 3-37 months respectively 
only slight morfological changes were observed in the kidneys. 
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In view of our findings, it is relevant to question whether the increasing use of CyA for 
treating psoriasis is justified. Since the disease tends to recur after CyA is 
withdrawn, prolonged or even permanent administration of the drug is likely to be 
required. Although our study among others clearly shows that therapeutic efficacy can be 
achieved at Cy A doses lower than those used in the past, we cannot exclude that, at least 
in some patients, harm could have been done to the kidney. Nevertheless, our preliminary 
experience in monitoring GFR and ERPF is encouraging. Although a significant number 
of patients had decreased renal function at some point during the study, most episodes 
improved or resolved with dose adjustment or discontinuation of the drug. In the few 
patients with persistently decreased GFR and ERPF after cessation of CyA, the drug-free 
period varying between 1-3 months was perhaps too short for a full recovery. Whatever 
the reason, serum creatinine and creatinine clearance appeared to be poor predictors of 
mild to moderate reduction in GFR in long-term treatment regimes with CyA. Our 
fmdings underscore the plea by Myers [38] and others [21,28,39] to monitor GFR during 
these regimes by other means than creatinine determinations alone (e.g. inulin or 
radiolabelled thalamate, EDTA or DTP A). If pre therapy and interval GFR determinations 
are performed and Cy A dose adjustments do not alleviate the depression of GFR, other 
forms of treatment should be considered. Clearly, additional studies are required to 
establish the risk of chronic irreversible renal damage. For the time being, in patients 
requiring long-term systemic therapy, it is problably wise to alternate systemic treatment 
regimes (cyclosporin A, methotrexate, photo-chemotherapy, retinoids) to reduce the 
toxicity of each type. 
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Table 1. Participating centers and numbers of patients they included 
center 
1. Rotterdam, University Hospital Dijkzigt 
2. Amsterdam, Free University Hospital 
3. Maastricht, University Hospital St. Annada! 
4. Heerlen, De Wever Hospital 
5. Helmond,St. LambertusHospital 
6. The Hague, Leyenburg Hospital 
number of patients 
12 
12 
16 
14 
10 
10 
74 
Table 2. Treatment with methotrexate, retinoids and PUV A, before start of cyclosporin A. Number of patients 
and period of treatment. Response: l=weak, 2=fair, 3=good. Remission period in weeks 
treatment 
methotrexate 
retinoids 
PUVA 
number 
of patients 
.. (%) 
16 (22%) 
29 (39%) 
56 (76%) 
periods 
of treatment 
(range, median) 
16 (1-11, 15) 
29 (1- 9, 1) 
56 (1- 8, 2) 
response remission in 
weeks 
2 3 (median) 
3 8 5 0-76 (2) 
4 13 12 0-80 (2) 
11 20 25 0-99 (4) 
Table 3. Summary of number of patients that could be scored as success, dose adaptations and drop-outs 
(for reasons see text) in part 1, of group A'and B 
Group A 
success 
drop-out 
total 
dose reduction 
original in A 
17 
3 
20 
switchAtoB 
10 
2 
12 
2 
134 
total 
27 
5 
32 
3 
GroupE 
36 
6 
42 
10 
Table 4. Changes in clinical and laboratory variables in relation to dose of cyclosporin A and 
mean blood levels of cyclosporin A during fixed-dose phase (first four weeks) 
Dose Blood Level 
r (n) Pvalue r (n) Pvalue 
Psoriasis area and severity index -0.28 <0.01 -0.29 <0.05 
(84) (60) 
Systolic blood pressure 0.08 NS 0.17 NS 
(84) (60) 
Diastolic blood pressure 0.22 <0.05 0.40 <0.001 
(84) (60) 
Mean blood levels 0.39 <0.01 not applicable 
(60) 
Serum creatinine 0.01 NS 0.25 0.06 
(84) (60) 
Calculated creatinine clearance -0.05 NS -0.39 <0.01 
(51) (51) 
Serum uric acid -0.08 NS 0.21 NS 
(77) (57) 
Serum potassium 0.22 <0.05 0.13 NS 
(81) (59) 
Serum magnesium -0.30 <0.01 -0.34 <0.02 
(70) (49) 
Serum total bilirubine 0.26 <0.05 0.47 <0.001 
(60) (60) 
Body weight 0.18 NS 0.21 NS 
(82) (60) 
r denotes Spearman's rank-correlation coefficient. n refers to the number of patients included in the 
computation of r. NS denotes not significant. Pvalues are two-tailed. The absolute change in the variable 
from before therapy to the fourth week was used for this analysis. 
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Table 5. Summary of side-effects: according to actual dose of cyclosporln A, 
at any time of the induction period (%) 
subjective complaints 
headache, dizziness 
fatigue 
paraesthesias, tremor 
muscle or joint pain 
gastrointestinal symptoms 
premature heart beats 
chills 
upper airway irritation 
burning eyes, ear pain 
objective signs 
hypertension 
gum hyperplasia 
hypertrichosis 
acne vulgaris 
potassium (>5.5 mmol/1) 
creatinine (> 30% over baseline) 
bilirubin (twice upper limit) 
basocellular carcinoma 
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2.5mg/kg/d 5mg/kg/d 
7 (22) 9 (21) 
1 ( 3) 1 ( 2) 
2 ( 6) 13 (31) 
2 ( 6) 3 ( 7) 
3 ( 9) 8 (19) 
1 ( 2) 
2 ( 5) 
3 ( 9) 2 ( 5) 
1 ( 3) 4 (10) 
1 ( 3) 7 (17) 
1 ( 3) 3 ( 7) 
2 ( 6) 10 (24) 
1 ( 2) 
4 (10) 
9 (21) 
2 ( 5) 
1 ( 2) 
Table 6. Changes in clinical and laboratory variables during the induction period 
PASI 
Blood pressure 
systolic 
diastolic 
Creatinine 
Creatinine clearance 
Glomerular filtration rate 
Effective renal plasma flow 
Uric acid 
Magnesium 
Potassiurp 
Bilirubine (total) 
Body weight 
* 
** 
*** 
<0.05 
<0.01 difference between groups 
<0.001 
After 4 weeks (fixed-dose) 
2.5mg 5mg 
mean ± SE percent change 
n=30 n=42 
-40 ± 5 -62 ± 3* 
-3 ± 2 0 ± 1 
-3 ± 2 5 ± 2*** 
7±3 11 ± 3 
-5 ± 3 -7 ± 2 
10 ± 6 8±3 
-2 ± 5 -14 ± 2** 
1 ± 1 4 ± 1 
27 ± 12 63 ± 12 
-1 ± 1 1 ± 1 
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After 12 weeks (adjusted dose) 
3.5mg 4.8mg 
mean ± SE percent change 
n=20 n=44 
-80 ± 3 -85 ± 3 
-2 ± 2 3±2 
0±2 5±2 
3±2 11 ± 2** 
-2 ± 2 -7 ± 2* 
-13 ± 2 -15 ± 2 
-19 ± 2 -14 ± 2 
3±2 4±2 
-6 ± 2 -10 ± 1 
0±2 4 ± 1 
34 ± 13 56± 11 
0 ± 1 1 ±I 
Table 7. Actual moment of drop-out in phase 2, related to cause, for group A and group B together 
month 3 4/5 6/7 8/9 10/11 12/13 14/15 
cause 
renal dysfunction 1 2 1 1 1 
hypertension 1 1 1 
relapse 2 4 2 2 4 9 
uncooperative 2 1 2 2 1 1 
side-effects 1 3 1 1 
Table 8. The causes and number of drop-outs in phase 2, for all centers*, and number of patients 
that completed the study till month 16-19 
center 2 3 
cause 
renal dysfunction 1 1 1 
hypertension 1 
relapse 1 9 5 
uncooperative 2 1 2 
side-effects** 1 3 
drop-outs 5 11 12 
completed 3 
* see Table 1. 
** hypertrichosis (4), depression (1), thyroid disease (1) 
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4 
4 
4 
1 
10 
3 
5 
2 
1 
4 
6 
6 (all) 
( 5) 
( 3) 
4 (23) 
3 (12) 
( 6) 
7 (49) 
2 (14) 
Table 9. Effects of one year exposure to cyclosporin A on blood pressure and renal function 
Time of exposure to Cy A 
Patients n=21 Baseline 3months 
mean±SEM mean±SEM 
Blood pressure* 116 ± 3/72 ± 2 130 ± 4/81 ± 4 
(mmHg) ala 
Heart rate 67 ± 2 68 ± 2 
(bpm) 
Serum creatinine 78 ± 3 85 ± 4 
(f.tmol/1) a 
Glomerular filtration rate 111 ± 7 96 ± 4 
(ml/min) a 
Effective renal plasma flow 492 ± 50 421 ± 27 
(ml/min) (n=16) a 
a denotes values that do differ significantly from baseline 
b denotes values that do differ significantly from values at 3 months 
measurements by an automatic blood pressure measurement device 
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12months 
mean±SEM 
122 ± 3/74 ± 3 
a,b/b 
65 ± 2 
86 ± 4 
a 
102 ± 6 
a 
451 ± 33 
a 
Table 10. Effect of cyclosporin A on the glomerular filtration rate (GFR) 
Study[ref] period CyAdose decline of GFR no. of patients 
(wks) (mg/kg/d) 
this study 12 4,3 -15% 35 
Powles eta! [36] 9 3 -10% 11 
Ellis eta! [18] 8 5,2 - 16% 34 
Gilbert eta! [28] 9 4,7 -52%* 5 
• concomittant use of diuretics and NSAIDs was allowed in this study. 
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Fig. 2. 
Mean Psoriasis Area and Severity Index (PAS I) per week 
for gronp A and group B in part 1. 
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Plot-diagram of parent cyclosporin A whole blood trough 
levels (ng/ml) versus dosage of the oral formulation 
(mg/kg/d) of 495 measure points, and regression 
(slope .41568, sig .0000) See text. o = 1, e = 10 
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Cockroft clearance (ml/min), serum creatinine (!lmol/1) and 
cyclosporin A dose (mg/kg/d), in week 0-12, for group A 
(2.5 mg/kg/d) and group B (5 mg/kg)d) 
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Fig.S. 
Changes in glomerular filtration rate (ml/min) and effective renal plasma 
flow (ml/min), values of baseline and CyA therapy compared (see text) 
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Fig. 6. 
Time plot diagrams of changes (%) in values of serum creatinine ([tmol/1), 
glomerular filtration rate (ml/min), effective renal plasma flow (ml/min) with mean 
values (*p <0.01, **p <0.017), b,efore during (month 3) and after CyA therapy 
(part 3), for. group A and B together 
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Summary 
In recent years, much attention has been focussed on cyclosporin A (CyA) as a new 
alternative drug for the treatment of recalcitrant disabling psoriasis vulgaris. This drug 
has the important advantage of being non-myelotoxic as compared to other 
immunosuppressants. In conjunction with the earlier reported data concerning the clinical 
use of CyA to treat severe psoriasis, three treatment schedules are outlined: short-term, 
intermittent and long-term. Uncontrolled treatment of psoriasis with CyA could increase 
the risk of irreversible renal damage. The use of CyA, therefore, requires a multi-
disciplinary approach in which regular consultations and monitoring by a dermatologist 
and, if warranted, by a nephrologist are imperative. 
Introduction 
Cyclosporin A (CyA) is a selective immunosuppressant which inhibits the production of 
interleukin-2 and interferon gamma by T-helper cells. Both these lymphokines play an 
essential role in the immune response. CyA was first used as an immunosuppressant in 
1977 to prevent organ graft rejection. Since then, its efficacy has also been assessed in 
autoimmune disorders [1] and diseases such as psoriasis vulgaris which have an 
acknowledged immunological background [2,3]. CyA has the important advantage of 
being non-myelotoxic as compared to other conventional immunosuppressants. 
At present, a review of the up-to-date clinical data on CyA for the treatment of psoriasis 
vulgaris seems warranted, since this drug offers an important new alternative for treating 
persistent therapy-resistant skin diseases, and since preliminary results of such therapies 
appear to be very promising [4-10]. Moreover, CyA in its present galenical formulation, 
is expected to receive official registration in the near future in Europe for treating severe 
psoriasis. The drug, however, is not without serious side effects. In this review, various 
aspects of this new therapy, including the side-effects and drug-interactions in the use of 
Cy A in the treatment of psoriasis vulgaris, are summarized. In addition, appropriate 
treatment schedules and safety guidelines based on recent data in the literature and our 
own recent clinical experiences are discussed. 
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Pharmacokinetics and blood trough-level limits 
The pharmacology of CyA was recently reviewed [4]. 
CyA is insoluble in water. For oral administration (drink solution or capsules), an 
emulsion based on olive-oil is used as a vehicle. Absorption of CyA varies considerably 
among individual patients. Generally between 30% and 50% of the administered dose is 
biologically available. Peak levels of CyA in the blood have been observed between 1 and 
8 h (average 3 and 4 h) after intake. The final elimination half-life of the drug is 14-27 h. 
The drug is generally administered twice daily, taking as a guide, the whole blood trough-
level value determined 12 hours after the last intake. Initially, appropriate adjustments in 
the 12-hourly dose are often necessary to obtain therapeutically effective trough-levels. 
Optimum trough-levels as determined by radioimmunoassay appear to be in the range of 
100-200 ng/ml during chronic administration. If the dose is altered, the new steady state 
is to be expected after 48 h [5]. 
It should also be realized that not only too low a dose, but also malresorption in the gut 
and the concomitant use of certain medicaments which reduce the blood trough-level of 
CyA could lead to an inadequate therapeutic effect (Table 3, page 19). 
Clinical Experiences 
The therapeutic potential of CyA in psoriasis was accidently discovered as a side-effect in 
1979 when patients with arthritis psoriatica were treated [6]. The first clinical trials were 
conducted from 1985 once stringent patient selection criteria and strict patient monitoring 
parameters had been established [7-12]. In these studies the drink solution containing 100 
mg/ml in 50 ml bottles was used. Recently the capsules of 100 and 25 mg came available. 
In open clinical trials, a relatively low dose of about 5 mg/kg/d was observed to have a 
beneficial therapeutic effect in patients with psoriasis vulgaris [7-10]. This was also 
confirmed in double-blind studies [11-12]. 
The remission is dependent on the dose and may vary from 30-35% after about 4 weeks 
of treatment at a dose of 2.5 mg/kg/d to 75% or higher at a dose of 5 mg/kg/d (Fig. 1), 
[7,8,13]. After prolonged treatment (for up to 12 weeks), however, a remission of about 
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60% has been obtained at a dose of 2.5 mg/kg/d (Fig. 1), [14]. Dose-fmding studies also 
indicated that a dose of 5 mg/kg/d or lower was able to maintain the already achieved 
disease remission at a level which was acceptable to the patient [15,16]. Even during a 
short therapy period of less than three months (crisis intervention), side-effects such as an 
increase in blood pressure and in serum creatinine level have been observed [7-12]. 
However, both these effects were reversible. 
Considerable remission was achieved within 8 weeks using an average dose of 3 mg/kg/ d 
CyA in patients who were started off on 1 mg/kg/d CyA, which was increased stepwise 
until the desired therapeutic effect was achieved [8]. There is no clear consistent 
correlation between the CyA blood trough-levels and its therapeutic effect in psoriasis [5]. 
To date, a rebound phenomenon upon termination of CyA-therapy is exceptional [17] and 
the induction of resistance to CyA (tachyphylaxis) during therapy has not been observed. 
Relapse (defined as a minimum of 50% return in the activity and the spread of the disease 
as compared to that observed before therapy) has been observed in all patients after 
stopping CyA therapy. The period of remission of the disease after discontinuation of 
CyA is in general unpredictable and may vary from several weeks to months [12]. On 
average, however, in a subgroup of patients with moderate disease activity, the disease 
does not relapse any quicker than that observed after discontinuation of photo-
chemotherapy (PUVA) or topical therapy with agents such as dithranol [18]. Since topical 
application of CyA at high concentrations (up to 10%) has no therapeutic effect in 
psoriasis (see Chapter 6), it has to be given orally [19]. 
Interactions and side-effects 
CyA is extensively metabolized by the cytochrome P-450 system in the liver and excreted 
via the bile into the feces [20]. Therefore owing to their effect on this cytochrome P-450 
system (induction or inhibition), concomitant use of some drugs may reduce or increase 
the rate of degradation of CyA [20]. This can lead either to sub-therapeutic or to toxic 
blood trough-levels of CyA at the same dose. An updated list of medicaments that interact 
with CyA is shown in Table 3, page 19. Drugs that increase the nephrotoxicity of CyA 
when used concomitantly are also shown in this Table. 
The most prominent side-effects of Cy A therapy are dose- and time-dependent 
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nephrotoxicity and hypertension. Additional side-effects which may occur include 
hyperkalaemia and liver function abnormalities, usually at the beginning of the therapy 
(average 4%). A reduction in the serum magnesium level has also been reported. 
Clinically evident side-effects are gingival hyperplasia and hypertrichosis. Subjective side-
effects include fatigue, gastrointestinal upsets, tremor, paraesthesias, slight myalgia and 
transient headaches. 
It has been well documented that immunosuppressed patients are at an increased risk for 
developing malignancies, especially of lymphoreticular origin and, among others, skin 
carcinomas [21]. However, at the currently recommended blood trough-levels of CyA, the 
incidence of lymphoproliferative disease is low [21]. The increased potential of PUV A 
and CyA for the induction of squamous cell carcinomas, in particular, should also be 
carefully considered [22]. 
Conditions for treatment 
It is essential that a clear agreement on the therapy schedule and on the termination of the 
therapy is established between the patient and the treating physician. Total withdrawal (or 
eventual dose reduction) of CyA is warranted if undesirable side-effects occur. 
Prior to therapy, an accurate medical history of the patient, especially concerning 
previous renal disorders, hypertension and medications, should be obtained. Thorough 
physical and dermatological examinations (including a cervical smear in women) should 
be performed to exclude any malignancy or infections [21]. Blood pressure should be 
determined on at least two occasions. It is mandatory to assess the renal function 
thoroughly at baseline. Serum creatinine levels should be determined twice after fasting 
and if possible, the glomerular filtration rate (GFR) and the effective renal plasma flow 
(ERPF) should also be measured. Blood samples should be obtained to determine serum 
electrolytes (Na, K, Mg), liver function (bilirubin, aminotransferases, alkaline-
phosphatase), serum-lipids, blood glucose level, erythrocyte and leukocyte proftles and 
protein spectrum [11,12,21]. 
The current absolute and relative contra-indications for the use of CyA are listed in Table 
I. 
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Choice of treatment schedule 
Possible schedules for optimal treatment can be evaluated on the basis of the activity of 
the disease prior to therapy and after taking into account the patient's previous 
experiences regarding the disease. To date, definite treatment schedules with maximum 
benefit-risk ratios of CyA therapy in different sub-groups of psoriasis vulgaris patients are 
difficult to establish since relapse of the disease is often unpredictable. In dermatological 
practice, however, three different basic approaches, as depicted in Fig. 2, may be 
considered in principle: "short-term treatment", "intermittent treatment" and a treatment 
for a relatively longer period, "long-term treatment" [13]. 
A short-term treatment 
Short-term treatment has been proposed by us as a safe treatment period varying from 3 
to a maximum of 12 months using doses between 2.5-5 mg/kg/d. This regimen has the 
advantage of achieving an acceptable therapeutic effect within a few weeks with none or 
minimal and reversible side-effects. The primary aim of the therapy should not be to 
achieve total remission, but a clinical state that is acceptable to the patient. A -dose of 
about 3 mg/kg/d seems to give the most favorable benefit-risk ratio [8,9,12]. Should there 
be no improvement after 2 weeks of treatment, the dose may be increased stepwise by 1 
mg/kg/d at 2 week intervals up to 5 mg/kg/d. If remission occurs, the dose may be 
reduced weekly by 0.5-1 mg/kg/d in order to establish the individual minimum effective 
dose to be able to continue the therapy within the framework of short-term treatment. 
Monitoring of side-effects is imperative for timely intervention such as dose reduction or 
total withdrawal of CyA [21,23]. 
Intermittent treatment 
Another possibility is an intermittent treatment schedule whereby the treatment is stopped 
once the disease has been sufficiently suppressed and is resumed after an interval (Fig. 2) 
[13, 15]. Since, in less extreme active psoriasis, the discontinuation of Cy A does not 
necessarily lead to an immediate relapse of the disease, it is sometimes possible to keep 
the disease under control by using two therapy periods of several months duration in a 
year [15,18]. This regime decreases the risk of irreversible renal damage and of a 
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persistent rise in blood pressure. 
Long-term treatment 
In chronically active psoriasis of prolonged duration and therapy resistance, in which 
remission is not easily obtained, discontinuation of CyA could lead to a rapid and severe 
exacerbation of the disease which is unacceptable to the patient [11]. In such cases, 
intermittent treatment is not sufficient and a relatively long-term treatment schedule, 
longer than 12 months (Fig.2), using low dose (maximum 5mg/kg/d) CyA is of 
considerable therapeutic benefit. If necessary, the treatment may be continued using the 
minimial effective dose. 
This regimen is particularly appropriate for plaque form psoriasis vulgaris. The 
therapeutic benefit of CyA in other forms of psoriasis has also been reported [24,25]. 
Monitoring of the patient 
Renal Function 
As mentioned previously, renal malfunction is one of the most common side-effects of 
CyA therapy [26-31]. Prolonged uncontrolled treatment with CyA could lead to 
irreversible renal damage (arteriolopathy, interstitial fibrosis) [31]. It is generally accepted 
that the occurrence of this side-effect varies markedly among individual patients and 
depends, among other things, on the dose and on the CyA trough-levels achieved. In 
order to obtain the maximum therapeutic effect with limited depression in renal function, 
the blood trough-level should not exceed 200 ng/ml. Native CyA can be determined using 
specific monoclonal antibody in a radioimmune-assay (RIA) or by high performance 
liquid chromatography (HPLC) [5]. 
Prior to therapy, serum creatinine should be determined on two occasions. Determinations 
of GFR and ERPF values prior to therapy are also recommended since the long-term 
nephrotoxic effects of CyA therapy in psoriasis are not yet known [28]. Serum creatinine 
should be determined at 2 week intervals during short-term treatment and repeated at 
monthly or six-weekly intervals thereafter. If there is a 30% increase in serum creatinine 
above the patient's baseline value or a 10%-15% reduction in creatinine clearance, the 
CyA dose should be reduced weekly by 0.5 mg/kg/d until the serum creatinine and/or 
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creatinine clearance value has returned to baseline. If this does not occur, CyA therapy 
must be discontinued. 
There is a lively discussion as to whether serum creatinine is sensitive enough to indicate 
the occurrence of renal damage at an early reversible phase [28,29,(see also Chapter 7)] 
and whether GFR and EPRF determinations are "preferable" or are "strictly indicated". A 
limited increase in serum creatinine, which does not respond to Cy A dose reduction, may 
be the first indication of irreversible renal damage and, as stated previously, the reason to 
discontinue therapy. 
For all CyA treatment schedules it is "preferable" to check every six months whether the 
true GFR, determined using inulin or radioisotope, is depressed, since a more or less 
normal GFR is essential for continuing the therapy, if necessary using a lower dose. In 
the short-term treatment schedule ( < 12 months), if GFR determination is not possible, 
serum creatinine should be monitored very closely. We consider it to be safe to monitor 
only this parameter during treatment periods of less than 12 months, because in psoriasis 
patients treated with CyA at doses of 1-5 mg/kg/d during a mean treatment period of 
about two years, the depression in GFR and EPRF were reversible [28]. 
A "sine qua non" for regular intermittent CyA therapy is that in the interval period, both 
serum creatinine and creatinine clearance values return to baseline. It is preferable to 
check that both GFR and ERPF, performed 3-4 weeks after the last treatment, have also 
returned to baseline. When the intermittent treatment schedule is used for several 
consecutive years, GFR and ERPF, however, are mandatory (Fig. 2). 
For continuous long-term treatment (> 12 months) serum creatinine (repeated every 4 - 6 
weeks), GFR and ERPF determinations (repeated every 6 months) are mandatory for 
further safe therapy. This is due to the fact that there is still uncertainty concerning the 
effect(s) on renal function of a long-term treatment regime possibly continued for several 
consecutive years. 
Blood pressure 
CyA therapy often results in increased blood pressure, which in some case can be serious. 
Blood pressure should be checked at 2-4 week interval. If, in spite of blood pressure 
reducing therapy with nifedipine (no ,8-blockers in psoriasis because of increased risk of 
exacerbation, no diuretics in case of abnormal renal function), the diastolic pressure rises 
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above 95 mm Hg, or the systolic pressure rises above 160 mm Hg, the dose of CyA 
should be reduced. If this reduction (0.5 mg/kg/d) has no effect, the therapy should be 
stopped. 
Clinical side-effects 
Clinical side-effects such as tremor, gingival hyperplasia and hypertrichosis abate when 
the dose is reduced. As well as the strict monitoring of blood pressure and of renal 
function, biochemical parameters should also be evaluated at least at monthly intervals 
and full blood counts determined at six-month intervals [23]. The risk for possible 
development of malignancies should be considered particularly during long-term treatment 
[32]. 
Combination with other (anti-psoriatic) drugs 
The combination of CyA with other anti-psoriatic drugs is still under investigation. For 
example, addition of retinoids did not convincingly reduce the amount of CyA required 
[15 ,33] and combination with PUV A-therapy [34] or methotrexate [35] had no therapeutic 
benefit. The use of UV radiation brings with it an increased risk of skin tumours. Topical 
therapies with tar, dithranol or steroid ointments pose no objections. 
An interesting new development is that fish oil, in particular the eicosapentanoic acids 
(EPA) present therein, appear to enhance the clinical effect of CyA [15] and reduce the 
adverse effect(s) of CyA on renal function. In a recent study, it was shown that psoriasis 
patients who were treated with both CyA and fish oil showed a marked reduction in renal 
function abnormalities as compared to those observed in patients who were treated with 
Cy A only. A possible explanation is that the formation of vasoconstrictive arachidonic 
acid metabolites is inhibited [36]. In a preliminary study [30], the frequency of CyA-
associated nephrotoxicity was lower in transplant patients who were treated transdermally 
with clonidine before and after surgery. The protective effect seemed not to be related to 
changes in blood pressure. These studies [36,37] have yet to be confrrmed. 
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Conclusions and recommendations 
In consultation with the patient, CyA should be reserved exclusively for recalcitrant 
disabling forms of psoriasis vulgaris. It has yet to be established which treatment schedule 
is of maximum therapeutic value for each category or sub-groups of severe psoriasis 
vulgaris patients. Long-term CyA treatment for very severe psoriasis should only be 
considered if the expected therapeutic benefit outweighs the eventual side-effects. In such 
cases, close monitoring of blood pressure and renal function is essential. There is no 
consensus yet on the procedure to follow once CyA therapy becomes contra-indicated and 
the disease relapses to a level unacceptable to the patient. 
It is our opinion that, for the time being, the use of CyA in the present galenical 
formulation should be confined to dermatology centers that not only have access to 
expertise in the use of CyA, but also possess the appropriate facilities for monitoring the 
long-term risks [5]. Treatment of psoriasis patients with CyA requires a multidisciplinary 
approach in which regular consultations with a dermatologist and if warranted, a 
nephrologist are imperative. 
Future developments should be directed towards new formulations of Cy A which have the 
same efficacy in psoriasis but which spare the kidney. 
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Table I 
Contra-indications for oral cyclosporin A in psoriasis. 
Absolute contra-indications . 
Immunocompromized patients. 
Abnormal renal functions. 
Uncontrolable hypertension. 
Acute viral or bacterial infections. 
Pregnancy or lactation. 
History of malignancy. 
Concomitant treatment with nephrotoxic drugs (Table 3, page 19) 
Concomitant treatment with Lovastatine or Simvastatin which predisposes to the 
occurrence of myopathy. 
Serious side effects of previous cyclosporin A therapy which did not improve 
upon dose-reduction. 
Hypersensitivity to cyclosporin A. 
Relative contra-indications 
Limited abnormalities in liver-functions. 
Epilepsy. 
Malabsoption syndrome. 
Drug and/or alcohol addiction. 
Drugs which interfere with the pharmacokinetics of cyclosporin A (Table 3, page 
19). 
Previous anti-psoriatic therapies (PUVA, methotrexate, arsenic) which may 
increase the risk of skin malignancies. 
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Summary and conclusions 
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Summary and conclusions 
This thesis deals with the application of cyclosporin A in the treatment of psoriasis. 
Chapter 1 
In this introductory Chapter the agent cyclosporin A is presented. An outline of its history 
is given from its discovery in the early seventies to drug of choice for immunosuppression 
in the majority of organ transplant centres in the world. The pharmacological and 
immunological properties of cyclosporin A are reviewed. In this respect the blockade of 
interleukin-2 is explicitly thought to be of major importance. The accidental success in an 
arthritis patient with psoriasis preluded many investigations in the field of dermatology. 
Apart from psoriasis a variety of skin disorders were screened for there reaction on 
cyclosporin A. Finally the known side-effects and drug interactions that limit its use are 
summarized. 
Chapter 2 
Different aspects of the skin disease psoriasis are brought forward in this second 
introductory chapter. The clinical picture is mostly formed by one or more efflorescences 
such as erythema, scales, papules, plaques or pustules. Histopathology is reviewed with 
reference to the clinical variability. Apart from genetics, triggering factors, biochemical 
and especially immunologic aspects are named here as pathomechanisms of psoriasis. The 
role of T -lymphocytes in the disease process are accentuated. Classical and newer therapy 
;nodalities both systemic and topical are named with special attention to their mechanism 
of action, exclusion criteria and side-effects for a better comparison with cyclosporin A. 
Chapter 3 
After several anecdotal reports on the effectiveness of cyclosporin A in psoriasis we were 
the first to treat 5 patients in an open prospective study and put them on 5 mg/kg/d, a 
lower dose than has been applied in organ transplantation so far. We selected patients 
with a severe form of psoriasis, resistant to conventional systemic treatment. In 3 patients 
an almost complete remission was seen and the rest improved considerably within 4 
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weeks. The mean reduction in the PASI (severity) score was 84%. There was evidence of 
slight renal dysfunction in one patient. We concluded that cyclosporin A was an effective 
treatment for the induction of a remission in severe psoriasis (crisis intervention). 
Chapter 4 
After the breakthrough experience in the pilot study a double-blind protocol was designed 
to treat 20 patients in the Departments of Dermatology of the University Hospital Dijkzigt 
and the Academic Medical Center in Amsterdam. In 4 weeks the patients received either 
low-dose cyclosporin A or placebo and the clinical results appeared to differ significantly. 
After 4 weeks 8 out of 10 placebo patients switched to active treatment and after another 
4 weeks they responded with a 90% reduction in PASI. In an attempt to maintain the 
remission we tapered the dose stepwise in a 2 months period and in 8 out of 9 patients 3 
mg/kg/d were effective. In a post-treatment observation phase 4 out of 5 patients relapsed 
after a mean interval of 6.5 weeks. Mild hypertension and elevated serum creatinine that 
occured in some patients were reversible. 
Chapter 5 
The results of short-term treatment with low-dose cyclosporin A were indeed encouraging 
but the disease tended to recur after withholding the drug. This was the reason to start a 
long-term evaluation of three dose regimes. Nineteen patients received either a continu-
ous, an intermittent treatment or a combination of cyclosporin A and the retinoic acid 
derivative TigasonR. This medicament has a proven antipsoriatic effect but can be 
hepatotoxic in therapeutic doses (see Chapter 2). 
The clinical effects of the continuous and intermittent regime were comparable, the side-
effects, however, were less in the latter approach because of a shorter exposition to the 
drug. In the combination we could not show a beneficial effect surpassing that of each 
drug given separately (in a low dose) or a cyclosporin A sparing effect. 
Chapter 6 
The side-effects of cyclosporin A became apparent in the initial high-dose programmes 
but remained bothersome also in the low-dose treatment protocols, especially nephrotoxi-
city and hypertension. To avoid these effects topical application seems a promising 
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solution. In this Chapter the topical use of cyclosporin A in psoriasis, alopecia, contact 
dermatitis, oral lichen planus and keloid scars is reviewed together with own experiences 
in some of these dermatological disorders. Apart from the intralesional and swish and spit 
method, no real clinical effect of topical formulations however, could be noticed. 
Theoretical considerations and suggestions for further investigations, such as the addition 
of penetration enhancers, complete this intriguing subject. 
Chapter 7 
To evaluate the clinical efficacy and safety of two dose regimes 2.5 and 5 mg/kg/d in 
severe psoriasis a trial had been started with 74 patients in 6 dermatological centers in 
The Netherlands. The severity and recalcitrant character of these patients' psoriasis is 
illustrated with the data of their acceptance and reactivity to conventional systemic 
treatment, such as methotrexate, photo-chemotherapy or retinoids. The 2.5 mg/kg/d dose 
appeared significantly less effective than the 5 mg/kg/d dose after 4 weeks. This higher 
dose however, required dose reductions for safety reasons in some 20% of the cases. In 
this period we analysed cyclosporine A trough levels with a monoclonal RIA kit and 
found an enormous interindividual variation. Serum creatinine in 4 weeks did not change 
on 2.5 mg/kg/d but increased 15% with the higher dose. For all the patients, glomerular 
filtration rate (GFR) and effective renal plasma flow (ERPF) fell about 13%. Additional 
treatment during at least 12 months with a stepwise dose reduction showed improvement 
in renal function. In the post-treatment observation phase serum creatinine was not 
significantly higher than baseline, GFR and ERPF remained under baseline 6 and 8 % 
respectively. In conclusion serum creatinine is not an ideal filtration marker. For long-
term treatment surveillance of renal function is mandatory with GFR or even better 
ERPF. Intermittent treatment with cyclosporin A alternated with conventional systemic 
treatment, however, needs further attention. 
Chapter 8 
The clinical and theoretical "academic" experiences are brought into one frame that can 
serve as safety guideline for the medical practioner. The pharmacokinetics are summari-
zed in conjunction with blood level estimation of cyclosporin A. A safe level range for 
parent cyclosporin A is advised in the range of 100-200 ng/ml. For induction of a 
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remission 5mg/kg/d of cyclosporin A seems insufficient, a start on lower doses can be 
effective but needs a stepwise increase of the dose. A rebound phenomenon or tachyphy-
laxis has not been observed. The relapse rate is unpredictable and varies from weeks to 
months. The interactions with nephro-and hepatotoxic drugs are stressed and the side-
effects reviewed. Patient selection criteria and contra-indications are given to prevent 
disappointing results. The short-term, intermittent and long-term regimes are then outlined 
together with suggestions for monitoring adverse effects, being mainly renal dysfunctions. 
Finally combination therapies are discussed, including the vasoprotective effect of fish-oil. 
In conclusion the clinical trials with oral cyclosporin A in severe and plaque psoriasis 
made it obvious that many patients, who suffered from this disabling skin disease really 
improved on this new oral therapy, mostly in a fast and convenient way. The impact on 
their lives, personally (improvement of body-image or strenghtening of ego) and as a 
consequence socially cannot be overestimated. If the safety rules given in detail in this 
thesis are followed accurately, major problems, especially avoidance of development of 
structural kidney changes, can be prevented. Both benevolent doctors and demanding 
patients - in their mutual dependency - have to be aware of the factors that determine the 
benefit-risk ratio of cyclosporin A therapy. In the future cyclosporin A can thus constitute 
an important treatment modality, next to conventional regimes such as methotrexate, 
photo-chemotherapy or retinoids in the immunoregulation of psoriasis variants. In addition 
the use of cyclosporin A in dermatological diseases can generate still more research that 
will provide a better insight into the immunomechanisms that are operative in these 
diseases. 
173 

Chapter 10 
Samenvatting en conclusies 
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Hoofdstuk 1 
In dit hoofdstuk wordt de stof cyclosporine A geintroduceerd. Er wordt een overzicht van 
zijn geschiedenis gegeven vanaf de ontdekking in het begin van de jaren '70 tot aan het 
moment dat het als eerste keuze geaccepteerd werd voor immunosuppressie in het 
merendeel van de centra voor orgaantransplantatie in de wereld. De pharmacologische en 
immunologische eigenschappen van cyclosporine A worden samengevat. In dit opzicht 
wordt de blokkade van interleukine-2 in het bijzonder van grote betekenis geacht. De 
behandeling van een patient met psoriasis arthropathica waarbij de huidafwijking 
toevalligerwijs goed reageerde, was een begin van veel onderzoek op het terrein van de 
dermatologie. Naast psoriasis werden nog bij talrijke andere huidziekten het effect van 
cyclosporine A onderzocht. Tenslotte worden de nu bekende bijwerkingen en de interne-
ties met geneesmiddelen, die het gebruik beperken, samengevat. 
Hoofdstuk 2 
Verschillende aspecten van de huidziekte worden in dit tweede inleidende hoofdstuk naar 
voren gebracht. Het klinisch beeld wordt meestal gevormd door het samengaan van enkele 
efflorescenties zoals erytheem, schilfering, papels, plaques of pustels. De histopathologie 
van psoriasis wordt samengevat in samenhang met de klinische wisselvalligheid. Naast 
genetische factoren worden uitlokkende momenten, biochemische en speciaal immunologi-
sche aspecten hier genoemd als de pathomechanismen van psoriasis. De rol van T-
lymphocyten in het ziekteproces wordt benadrukt. De klassieke en nieuwere behandelwij-
zen, zowel systemisch als locaal toegepast, worden op een rij gezet, met speciale aandacht 
voor hun aangrijpingspunten, exclusie criteria en ongewenste neveneffecten om zo beter te 
kunnen vergelijken met cyclosporine A. 
Hoofdstuk 3 
Na enige berichten, steeds een enkele patient betreffend, over de werkzaamheid van 
cyclosporine A bij psoriasis waren wij de eersten die vijf patienten behandelden in een 
zogenaamde "open prospectieve studie". Zij werden ingesteld op 5 mg/kg/dag, een lagere 
dosis dan tot dusver toegepast was bij orgaantransplantaties. Aleen patienten met een 
ernstige psoriasis die resistent was tegen in gebruik zijnde systemische behandelwijzen 
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namen deel. Bij drie patienten werd een bijna volledige remissie gezien en de rest 
verbeterde sterk in vier weken tijds. De gemiddelde afname van de graad van ernst, 
gemeten met de PASI-score was 84%. Er was een aanwijzing voor een lichte nierfunctie-
stoornis bij een patient. We trokken de conclusie, dat cyclosporine A een werkzame 
behandeling vormde voor het op gang brengen van een remissie bij ernstige psoriasis 
(crisis interventie). 
Hoofdstuk 4 
Na de opzienbarende ervaring in de "pilot study" werd een dubbel-blind protocol 
ontworpen om 20 patienten te behandelen op de afdeling voor Huidziekten van het 
Dijkzigt Ziekenhuis te Rotterdam en van het AMC te Amsterdam. Vier weken lang 
ontvingen patienten een lage dosis cyclosporine A dan wei een placebo (nepmiddel). De 
klinische resultaten bleken significant te verschillen. Na verloop van vier weken werden 
acht van de tien placebo-patienten overgezet op actieve behandeling. Na nog vier weken 
had den zij gereageerd met een P ASI vermindering van 90%. In een poging om de 
remissie te bestendigen, verminderden wij de dosis stapsgewijs in een periode van twee 
maanden. Bij acht van de negen patienten was 3 mg/kg/dag nog werkzaam. In een 
beoordelingsfase, volgend op de behandeling kregen vier van de vijf patienten opnieuw 
huidafwijkingen na een gemiddeld tijdsbestek van zes en een halve week. De milde 
hypertensie en gestegen serum creatinine waarde, die bij enkele patienten optrad, keerden 
naar de norm terug. 
Hoofdstuk 5 
De resultaten van de kortdurende behandeling met een lage dosis cyclosporine A waren 
inderdaad hoopgevend, maar de ziekte neigde de kop op te steken als het middel werd 
gestaakt. Dat was de reden om een lange termijn behandeling te starten met het doel drie 
doseerregimes te vergelijken. Negentien patienten kregen een continue of een interrnitte-
rende behandeling, dan wel een combinatie van cyclosporine A en de van vitamine A 
zuur afgeleide stof TigasonR. Dit geneesmiddel heeft een bewezen antipsoriatische 
werking, maar het kan leverbeschadiging geven in de werkzame dosis (zie Hoofdstuk 2). 
Ret klinisch effect van het continue en intermitterend beleid was vergelijkbaar. De 
nevenverschijnselen evenwel waren bij de laatste variant minder tengevolge van de 
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kortere tijd dat de patient aan het middel had blootgestaan. Bij de combinatiebehandeling 
konden wij geen positief effect aantonen dat sterker was dan het effect van elk middel 
afzonderlijk - en in lage dosering - of een cyclosporine A sparend effect. 
Hoofdstuk 6 
De neveneffecten van cyclosporine A werden duidelijk in de oorspronkelijke behandel-
schema's met een hoge dosering, maar bleven ook hinderlijk in de schema's die uitgingen 
van een lagere dosering, met name nierbeschadiging en hypertensie. De toepassing op de 
huid of slijmvliezen lijkt een veelbelovende oplossing om deze invloeden te vermijden. In 
dit hoofdstuk wordt een overzicht gegeven van de locale toepassing van cyclosporine A 
bij psoriasis, alopecia, contact eczeem, orale lichen planus en keloidale littekenreacties, 
tezamen met onze eigen ervaringen met enkele van deze huidziekten. Uitgezonderd de 
intralesionale en "mondspoel-en-spuw" methode, kon echter van de locale toedienings-
vorm geen werkelijk klinisch effect worden opgemerkt. Theoretische overwegingen en 
suggesties voor verder onderzoek, zoals het gebruik van penetratieversnellers, vormen het 
besluit van dit intrigerende onderwerp. 
Hoofdstuk 7 
Om het klinisch effect en de veiligheid van twee doseerschema's te vergelijken, n.l. 2,5 
en 5 mg/kg/dag, werd een onderzoek gestart met 74 patienten in zes dermatologische 
centra in Nederland. De ernst en het therapie-resistente karakter van de psoriasis van deze 
patienten wordt toegelicht met de gegevens over de acceptatie en de reactie op de 
gebruikelijke systemische behandeling, zoals methotrexaat, photochemotherapie of 
retinoi:den. De 2,5 mg/kg/dag dosis bleek significant minder werkzaam dan de 5 mg/kg-
/dag dosis na vier weken. Deze hogere dosis echter behoefde reductie uit veiligheidsover-
wegingen in ongeveer 20% van de gevallen. In deze periode analyseerden wij de 
cyclosporine A dalspiegels met een monoclonale RIA kit en vonden sterk wisselende 
interindividuele waarden. Ret serum creatinine niveau veranderde in vier weken op 2,5 
mg/kg/dag niet, maar steeg 15% onder invloed van de hogere dosis. Bij al de patienten 
daalden de glomerulair filtratie snelheid (GFR) en de effectieve renale plasma flow 
(ERPF) ongeveer 13%. Onder voortgezette behandeling gedurende tenminste twaalf 
maanden, met een stapsgewijze vermindering van de dosis, werd een verbetering van de 
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nierfunctie zichtbaar. In de controleperiode na de behandeling was het serum creatinine 
gehalte niet significant hoger dan de uitgangswaarde. De GFR en de ERPF bleven resp. 6 
en 8% onder de uitgangswaarde. 
Samenvattend kan gesteld worden, dat de serum creatinine waarde geen ideale maat is 
voor de filtratie. Kortom tijdens een langdurige behandeling is de bewaking van de 
nierfunctie noodzakelijk door middel van de GFR of nog beter door de ERPF. Een 
intermitterende behandeling met cyclosporine A, afgewisseld met een gebruikelijk 
systemische behandelwijze, verdient uit veiligheidsoverwegingen alle aandacht. 
Hoofdstuk 8 
De klinische en theoretische "academische" ervaringen worden nu in een raamwerk 
gebracht, dat kan dienen als veiligheidsvoorschrift voor de medicus practicus. De 
pharmacokinetiek wordt samengevat in samenhang met bloedspiegelbepalingen van 
cyclosporine A. Als veilige grenzen voor het cyclosporine A zelf, zonder metabolieten, 
wordt geadviseerd om 100-200 ng/ml aan te houden. Om een remissie te bewerkstelligen 
lijkt 5 mg/kg/dag voldoende. Beginnen met een lagere dosis kan werkzaam zijn, maar 
behoeft een stapsgewijs ophogen van de dosering. Een zogenaamd rebound verschijnsel en 
tachyphylaxie worden niet waargenomen. De snelheid waarmee de huidafwijkingen 
opnieuw terugkeren is onvoorspelbaar en wisselt van weken tot maanden. De interacties 
met nier-en leverbeschadigende geneesmiddelen worden benadrukt en de neveneffecten 
worden op een rij gezet. De criteria voor de selectie van patienten en de contra-indicaties 
worden gegeven om teleurstellende resultaten te voorkomen. Vervolgens worden de korte 
termijn, de intermitterende en de lange termijn regimes besproken, tezamen met aanbeve-
lingen om het ontstaan van neveneffecten te bewaken, met name nierfunctieverlies. 
Tenslotte worden combinatietherapieen, inclusief het beschermend effect van visolie op de 
bloedvaten, van commentaar voorzien. 
Samenvattend kan gesteld worden, dat de klinische onderzoekprogramma's met cyclospo-
rine A bij het ernstige ziektebeeld van de psoriasis en plaque ons geleerd hebben dat vele 
patienten, die gebukt gingen onder de zo ernstig invaliderende ziekte, werkelijk verbeter-
den op deze nieuwe orale therapie en meestal op een snelle en gemakkelijke manier. De 
invloed op hun leven, persoonlijk - door een verbetering van hun lichaamsbeeld of de 
versterking van hun ego - en dientengevolge sociaal, kan niet overschat worden. Als de 
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veiligheidsnormen, die in dit proefschrift in detail zijn gegeven, zorgvuldig worden 
nagevolgd, kunnen grote problemen, in het bijzonder de ontwikkeling van structurele 
nierbeschadiging, voorkomen worden. Welwillende dokters evengoed als mondige 
patienten, dienen - in hun wederzijdse afhankelijkheid - zich bewust te zijn van de 
factoren die het evenwicht van voor-en nadelen van een cyclosporine A therapie bepalen. 
Aldus kan cyclosporine A in de toekomst een belangrijke behandelmogelijkheid vormen 
naast in zwang zijnde regimes zoals methotrexaat, photochemotherapie of retinoiden. 
Bovendien zal het gebruik van cyclosporine A bij huidziekten nog meer onderzoek op 
gang brengen, dat een beter inzicht kan verschaffen in de immunologische mec~anismen, 
die in deze ziektebeelden werkzaam zijn. 
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ADDENDUM 1 P ASI scoring list 
Project 
Center VISIT Patient No. oLUJ Sandimmune® 3 
No. LlJ in therapy resistant plaque type psoriasis Initials 
Date I 
' 
I I I Investigator WEEK of exam. 
1 Day Month Year 
Psoriasis Area and Severity Index (PASI) 
Scoring svstem 
Score I o 11 I 2 I 3 14 I s I s 
Erythema 
I 
none I slight 
I 
moderate I severe I ve~ 
I 
-
I 
-
Infiltration severe 
Desquamation 
Area% I o I c10 I 10c30 I 30c50 I 50c70 1 70<90 I I 90-100 
HEAD (H) TRUNK (T) 
Score Score 
E~hema D E~hema D 
Infiltration D Infiltration 0 
Desquamation 0 Desquamation D 
Sum rn Sum rn 
x Area 0 x Area D 
=-~ 
= rn = rn 
X 0,1 = ITO X 0,3= ITIJ 
UPPER LIMBS (UL) LOWER LIMBS (LL) 
Score 
E~hema D 
Infiltration 0 
Desquamation D 
Sum rn 
x Area 0 
= rn 
X 0,2 = ITIJ 
PAS!= (H)+(TJ+(UL)+(LL)= I I I 1+1 I I I+ I 
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E~hema 
Infiltration 
Desquamation 
Sum 
x Area 
= 
X 0,4= 
I I 1+1 I 
Score 
D 
D 
D 
rn 
0 
=---= 
I I = 
Fredenksson T 
Petterson U 
rn 
[OJ 
I I I I 
Dermatologica 1978; 157; 238-A4 

Addendum 2 Colour Plates 
Plate 1. Trunk. Psoriasis vulgaris, before cyclosporin A treatment 
Plate 2. Trunk. Psoriasis vulgaris, after 4 weeks cyclosporin A treatment 
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Colour Plates 
Plate 3. Upper leg left. Psoriasis vulgaris, before treatment 
Right. Mild relapse 3 weeks after withdrawal of cyclosporin A treatment 
Plate 4. Mouth. Side-effect of cyclosporin A treatment: 
Gingiva Hyperplasia. After 6 weeks 
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Colour Plates 
Plate 5. Trunk. Before cyclosporin A treatment. Psoriasis elsewhere on the body 
Plate 6. Trunk. Side-effect of cyclosporin A treatment 
Hypertrichosis. After 6 weeks 
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Colour Plates 
Plate 7. Histopathology of a psoriasis lesion. Haematoxylin-eosin staining 
Plate 8. Same section as Plate 7. Staining with anti-Leu 3a monoclonal antibodies 
shows dermal infiltrate consisting of T helper lymphocytes. 
I 
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Addendum 3 
List of abbreviations 
APC 
BFC 
BP 
BW 
CARA 
Ci 
CRABP 
CyA 
D 
DMSO 
DNFB 
DTH 
E 
EDTA 
EGF 
EPA 
ERPF 
F 
FA 
FNA 
FPIA 
GFR 
HLA 
HPLC 
ICAM 
IFN 
IgE 
antigen presenting cell 
blister fluid concentration 
blood pressure 
body weight 
chronic a-specific respiratory disease 
creatinine clearance calculated with Cockcroft's formula 
Curie 
cellular retinoid binding protein 
cyclosporin A 
Dalton 
dimethylsulphoxide 
dinitro fluorbenzene 
delayed type hypersensitivity 
exacerbation 
edetic acid 
epidermal growth factor 
eicosa pentanoic acids 
effective renal plasma flow 
failure 
fumaric acid 
formularium Nederlandse Apothekers 
fluorescence-polarization immuno assay 
glomerular filtration rate 
human leucocyte antigen 
high performance liquid chromatography 
intercellular adhesion molecule 
interferon 
immunoglobulin E 
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IL 
INH 
IP 
iv 
LFA 
M 
MTX 
NSAID 
ODC 
PAF 
PASI 
PMNL 
PUVA 
interleukin 
isoniazide 
initial P ASI 
intravenous 
lymphocyte function associated antigen 
maintenance 
methotrexate 
non steroid anti-inflammatory drug 
ornithine decarboxylase 
platelet activating factor 
psoriasis area and severity index 
polymorphonuclear leucocyte 
psoralen and UV-A or photo-chemotherapy 
re-PUV A retinoids combined with PUV A 
RI remission induction 
RIA radioimmunoassay 
SRT signed rank test 
TP A tumor promoting phorbol ester 
UV ultraviolet light 
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een sterk klinisch accent aan de studie te geven. Aan de vele stimulerende gesprekken 
denk ik met genoegen terug. 
Dr. G.J. Wenting, Gert-Jan, hartelijk dank voor je inzet met de medewerkers van de 
afdeling Nephrologie, voor de kritische bewaking van de "gezonde" populatie patienten, 
die we exposeerden aan cyclosporine A. Je magisch realisme bij het totstandkomen van 
Hoofdstuk 7 bewonder ik. 
De leden van de promotiecommissie, Prof. dr. R. Benner, Prof. dr. P.R. Saxena en Prof. 
dr. M.A.D.H. Schalekamp noem ik gaarne omdat ze dit proefschrift becommentarieerden. 
Dr. J.W.O. van der Berg en zijn laboratoriummedewerkers dank ik voor de talloze 
cyclosporine-spiegel bepalingen en technische adviezen dienaangaande, evenals Dr. Th. 
Stijnen van de afdeling Biostatistiek van de Erasmus Universiteit, die deels in samenwer-
king met Drs. A. Bosman waardevolle adviezen gaf voor de bewerking van een vloed van 
getallen. 
Mijn dank gaat ook naar de collegae dermatologen in de participerende ziekenhuizen van 
Amsterdam (VU), Heerlen, Maastricht, Helmond en Den Haag. Het regelmatig overleg 
was zakelijk en productief, maar had telkens toch een persoonlijk (en culinair) cachet. 
Speciaal wil ik in dit verband noemen de samenwerking met de afdeling Dermatologie 
van het Academisch Medisch Centrum te Amsterdam (Hoofd Prof. dr. J.D. Bos). 
Dr. B. Tank dank ik voor de zorgvuldige controle van de Engelse tekst en talloze 
praktische suggesties, evenals mevrouw H.H. de Klerk-Teule, die de Nederlandse tekst 
corrigeerde. 
189 
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assistenten Ronald Laeijendecker en Mente Bousema, inmiddels dermatoloog, hebben veel 
werk verzet. 
Voor de technische assistentie dank ik mevrouw Wil Voermans, die de tekst nog eens 
helemaal uitgetypt heeft en samen met de heer Hans Moes de lay-out voor haar rekening 
nam, alsook de heer Johan van der Stek, die het fotowerk verzorgde en mevrouw Joke 
Pepermans, die de grafieken tekende. 
Voor de bereidwilligheid om mee te werken aan de onderzoeken ben ik al de patienten 
zeer erkentelijk. Zij bleven trouw, mede dankzij de aandacht en zorg van de verpleging 
van de kliniek (Hoofd: Zr. L. Agerbeek) en de polikliniek (Hoofd: Zr. M.G. Kenswil) en 
hun medewerkers. Zonder de nauwgezette monitoring van de trials en de steun van de 
firma Sandoz, in het bijzonder van de heer J. Stokvis had ik dit werk niet kunnen doen. 
Allen die mij fysiek op de been hielden tijdens deze excercitie, ook al liep alles ogen-
schijnlijk op rolletjes ben ik zeer dankbaar. 
Tenslotte dank ik jullie, mijn lieve vrouw en jongens, voor het geduld dat jullie hebben 
opgebracht in de periode dat ik "aan een vlaag van wetenschap leed". 
Ter nagedachtenis aan Prof. dr. G.L. Kalsbeek 
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